

CURRICULUM VITAE

JULIE RUTH GRALOW

Undergraduate Education:

9/77 - 6/81 Stanford University. Stanford, California. B.S. in Biological Sciences.

Medical Education:

9/84 - 5/88 University of Southern California School of Medicine. Los Angeles, California. M.D. degree.

Internship and Residency Training:

6/88 - 6/91 Department of Internal Medicine. Brigham and Women's Hospital, Harvard Medical School. Boston, Massachusetts.

Fellowship Training:

7/92 - 7/95 University of Washington/Fred Hutchinson Cancer Research Center, Medical Oncology Fellowship Program. Seattle, Washington.

Employment/Research Experience:

3/21 - present Professor Emeritus. Medicine/Oncology, University of Washington School of Medicine

2/21 - present Executive Vice President and Chief Medical Officer. American Society of Clinical Oncology (ASCO)

1/19 - 2/21 Medical Director. Women's Cancer-related Population Health. Seattle Cancer Care Alliance and University of Washington

8/12 - 2/21 Jill Bennett Endowed Professor of Breast Cancer. University of Washington School of Medicine

5/12 - present Adjunct Professor. Department of Global Health, University of Washington School of Medicine and School of Public Health

10/11 - 2/21 Faculty Member. Ellison Center for Russian, East European and Central Asian Studies, Henry M. Jackson School of International Studies, University of Washington

7/11 - 2/21 Professor. Clinical Research Division, Fred Hutchinson Cancer Research Center

7/09 - 2/21 Professor. Department of Medicine, Division of Oncology. University of Washington School of Medicine

9/07 - 2/21 Director, Breast Medical Oncology. University of Washington and Seattle Cancer Care Alliance

7/06 - 6/11 Associate Professor. Clinical Research Division, Fred Hutchinson Cancer Research Center

7/02 - 6/09 Associate Professor. Department of Medicine, Division of Oncology. University of Washington School of Medicine

7/01 - 2/21 Associate Program Head. Breast and Ovarian Cancer Program, Fred Hutchinson Cancer Research Center

1/99 - 7/06	<u>Assistant Professor</u> . Clinical Research Division, Fred Hutchinson Cancer Research Center
1/98 - 2002	<u>Assistant Professor</u> . Department of Medicine, Division of Oncology. University of Washington School of Medicine
1/98 - 2002	<u>Director</u> . University of Washington Women's Cancer Genetics and Risk Reduction Clinic
1/98 - 2002	<u>Director</u> . Patient and Physician Education and Outreach. University of Washington Cancer Center
7/94 - 12/97	<u>Acting Instructor</u> . Department of Medicine, Division of Oncology. University of Washington School of Medicine
7/91 - 6/92	<u>Staff Internist</u> . Harvard Community Health Plan. Boston, Massachusetts
1985, 1986	<u>Summer Research Fellow</u> . Laboratory of Peter A. Jones, Ph.D. Department of Biochemistry, Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine
1983 - 1984	<u>Research Assistant</u> . Laboratory of Ronald Levy, M.D. Division of Oncology, Stanford University School of Medicine
1981 - 1983	<u>Research Assistant</u> . Laboratory of Richard Miller, M.D. Becton Dickinson Monoclonal Center. Mountain View, California

Board Certification:

Medical Oncology 9/95, recertified 2005, 2016

Internal Medicine 9/91

Medical Licenses:

Washington State Physician and Surgeon's License Number: MD00029516 (expiration 2-10-25)

DEA Registration Number: BG2706034 (expiration 9-30-23)

Society Memberships:

American Society of Clinical Oncology

American Association for Cancer Research

SWOG Cancer Research Network

European Society of Medical Oncology

American Society of Clinical Pathology

American Society of Breast Disease

Washington State Medical Oncology Society

American College of Physicians

Honors and Awards

University of Washington School of Medicine Humanitarian Award 2023

Healio/HemeOnc Today Lifetime Disruptor Award 2023

Binaytara Foundation Humanitarian Award 2022

OncLive Giants of Cancer Care Award for Community Outreach/Policy 2021

American Society of Clinical Oncology (ASCO) Humanitarian Award 2018

Pillar of Support Award, African First Ladies against Cervical, Breast and Prostate Cancer 2016

Seattle Business Magazine Leaders in Healthcare Achievement in Community Outreach Award, 2014

Team Survivor Northwest "Gralow Award" for Outstanding Support of Team Survivor Northwest, 2013

Fellow, American College of Physicians (FACP), elected 2008

Fellow, American Society of Clinical Oncology (FASCO) (Statesman Award), 2008

University of Washington Medical Center Service Excellence Award, 2008

NCI Certificate of Appreciation for Significant Contributions as Co-Chair of NCI's State of the Science Conference on Preoperative Therapy in Breast Cancer, 2007
 Susan G. Komen for the Cure, Puget Sound Affiliate, Community Service Award to the "Finding Your Way to Wellness" Committee, 2007
 Helen H. Jackson "Women of Valor" Award for Medicine and Health Care, Washington State, 2006
 "Above and Beyond" Award, The Breast Care Site, December 2005
 Susan G. Komen for the Cure, Puget Sound Affiliate, C.J. Taylor Outstanding Community Volunteer Award, 2005
 University of Washington Continuing Medical Education Department Outstanding Faculty Award, 2000
 Coping Magazine Honorary Hero 1999
 American Society of Clinical Oncology Career Development Award 1995-1998
 Upjohn Outstanding Oncology Fellow Award 1994
 Irving I. Lasky Award for Medical Student Research 1988
 Janet M. Glasgow/American Medical Women's Association Achievement Award 1988
 Alpha Omega Alpha Honor Medical Society, elected 1986
 U.S.C. School of Medicine Dean's List: 1984/85, 1985/86, 1986/87, 1987/88
 Western Student Medical Research Committee: member 1985/86, vice-chairman 1986/87, chairman 1987/88
 U.S.C. Summer Research Fellowship Award 1984/85, 1985/86

Committees and Activities:

University of Washington
 Member, Department of Medicine, Professors' Review Committee 2020-2021
 Member, University of Washington Breast Cancer Equity Initiative, 2020-2021
 Senator, University of Washington Faculty Senate 2002-2004
 Member-at-Large, University of Washington Medical Staff Advisory Committee, 1998-2006
 Co-Director, University of Washington Medical Center Patient and Family Education Committee 1996-2003
 Member, University of Washington School of Medicine Human Subjects Review Committee 1998 - 2000
 Fred Hutchinson Cancer Research Center
 Member, Leadership Team, Fred Hutch Lead Academic Participating Site (LAPS) 2014-2021
 Member, Scientific Steering Committee 2002-2021
 Associate Program Head, Breast and Ovarian Cancer Program 2001-2021
 SWOG Cancer Research Network
 Executive Officer, Breast and Lung Cancer 2013-2021
 Vice-Chair, Breast Cancer Committee 2000-2013
 Member, International Working Group/Latin America Initiative 2014-2021
 Member, Publications Committee 2014-2021
 Member, Digital Engagement Committee 2016-2021
 Executive Committee Member, Committee on Special Populations/Survivorship 1995-2010
 American Society of Clinical Oncology (ASCO)
 Editorial Board, ASCO/ESMO Global Curriculum in Medical Oncology, 2020-2021
 Member, ASCO Chemo and Targeted Therapy for Advanced HER2- Breast Cancer Guideline Panel, 2019-2021
 Member, ASCO Osteonecrosis of the Jaw Consensus panel 2018-2021
 Member, ASCO Special Awards Committee 2018-2021
 Chair, ASCO Academic Global Oncology Task Force 2017-2019
 Co-Chair, ASCO Resource Stratified Guideline Advisory Group 2016-2021

Member, ASCO Cancer Education Committee, Global Health Track, 2016 - 2018
 Member, ASCO Breast Cancer Guideline Advisory Group 2014-2018
 Member, ASCO-CAP Panel on Enhancing Pathology in Developing Countries 2015-2016
 Member, ASCO Global Oncology Leadership Task Force 2014-2016
 Member, ASCO International Affairs Committee 2013-2016
 Mentor, ASCO International Development and Education Award (IDEA) 2010, 2014, 2015, 2018
 Member, ASCO Nominating Committee (elected position) 2008-2011
 Member, ASCO Cancer Communications Committee 2005-2009, Chair 2007/2008
 Chair, ASCO Patient Communication Subcommittee 2005-2007
 Member, ASCO Public Issues Committee 1999-2004; Co-Chair, 2000-2002
 Member, ASCO Program Committee 2000
 Member/Liaison, ASCO Health Services Research Committee 2000-2004
 American Society for Clinical Pathology (ASCP)
 Co-chair, Care and Treatment Committee of ASCP Partners in Cancer Diagnosis and Treatment program 2016-2019
 Advisory Committee Member, ASCP Partners for Cancer Diagnosis and Treatment Initiative 2019-present
 Global Medical Knowledge Alliance, Board of Advisors 2022-present
 National Cancer Policy Forum
 Member 2021-present
 Sharing Progress in Cancer Care
 Scientific Advisory Board, 2022-present
 Women's Empowerment Cancer Advocacy Network (WE CAN)
 Founder and Director, 2003-2021
 Global Task Force on Expanded Access to Cancer Care and Control in the Developing World
 Task Force Member 2009-2014, Co-Secretariat 2012-2014
 Breast Cancer Initiative 2.5 (BCI2.5) Global Campaign
 Co-Chair, Secretariat 2015 – 2021
 BioVentures for Global Health (BVGH)
 Member, Board of Directors 2023-present
 Member, Steering Committee, African Consortium for Cancer Clinical Trials (AC3T) 2017-present
 Susan G. Komen for the Cure
 Member, National Scientific Advisory Council 2010-2017
 Board Member, Puget Sound Affiliate of Susan G. Komen for the Cure 1996-2001
 Advisory Board Member, Puget Sound Affiliate Susan G. Komen for the Cure 2004-2020
 East Africa Center of Excellence in Oncology at the Uganda Cancer Institute, Adult Hematology-Oncology Fellowship Training Program
 Advisory Council Member, 2017-2021
 National Women's Health Resource Center
 Member, Breast Health Advisory Panel 2005-2015
 Peace Island Medical Center, San Juan Island, Washington
 Board Member, 2012-present
 Editorial Boards
 Editor, Breast Cancer, ASCO Cancer.Net 2009-2012
 Section Editor, Breast Cancer, UpToDate 2009-2015
 Editorial Board, Journal of Bone Oncology 2011-2018
 Editorial Board, Breast Diseases 2005-2016
 Editorial Board, The Breast Journal 2006-2018

Editorial Board, Clinical Cancer Advances 2006-2009
 Editorial Advisor, Advances in Targeted Cancer Therapies, 2003-2007
 Grant Reviews and Study Sections
 National Cancer Institute Global Cancer Research D-43 Study Section, 2020-2021
 Department of Defense Breast Cancer Research Program, Immunological Sciences and Clinical Trials Study Sections, 2001, 2002, 2003, 2005, 2007, 2009, 2011, 2012
 Department of Defense Breast Cancer Research Program, ad hoc Integration Panel Member, 2004, 2008, 2010, 2014, 2015, 2017, 2018
 Susan G. Komen for the Cure Grant Program, Pathobiology, Micrometastases and Clinical Trials Study Sections, 2008-2016
 National Cancer Institute Study Section H, Committee Member 2008-2012
 National Cancer Institute Prognostic and Predictive Markers Study Section, 2003-2004
 National Cancer Institute Clinical Oncology Study Section, 2004
 PATH/USAID Ukraine Breast Cancer Assistance Project
 Consultant, 1997-2000
 Team Survivor Northwest
 Co-founder and Member, Medical Advisory Committee, 1995-present
 Cook for Your Life
 Medical and Scientific Advisory Board, 2020-present
 Expedition Inspiration Breast Cancer Foundation
 Member, Medical Advisory Board 1999-present; Chair 2001-2007
 Living Beyond Breast Cancer
 Member, Professional Advisory Committee 2005-present
 Advocacy Advisory Committee 2010-present
 Gilda's Club/Cancer Pathways Seattle
 Member, Medical Council 2010-present
 Cierra Sisters African American Support Group
 Member, Medical Advisory Board 2010-present
 Breast Cancer.org
 Member, Professional Advisory Board 2004-present
 ÷ Global Focus on Cancer
 Member, Medical Advisory Board, 2016-present
 4aWoman/Akbaraly Foundation Project against Gynecologic and Breast Cancer in Madagascar
 Member, Scientific Advisory Board 2011-present
 American Cancer Society
 Director, University of Washington Medical Student Summer Research Fellowship Program 1996-2021

Publications:

1. Miller RA, Gralow J. The Induction of Leu-1 Antigen Expression in Human Malignant and Normal B-Cells by Phorbol Myristic Acetate. Journal of Immunology, 133: 3408-14, 1984.
2. Sklar J, Cleary ML, Thielmans K, Gralow J, Warnke R, Levy R. Biclinal B-Cell Lymphoma. New England Journal of Medicine, 311:20-27, 1984.
3. Thielmans K, Maloney DG, Meeker T, Fujimoto J, Doss C, Gralow J, Miller RA, Levy R. Strategies for the Production of Monoclonal Anti-Idiotypic Antibodies Against Human B-Cell Lymphomas. Journal of Immunology, 133: 495-501, 1984.

4. Levy R, Meeker TC, Lowder JN, Maloney D, Thielmans K, Gralow J, Warnke R, Cleary ML, Sklar J. The Immunology of B-Cell Lymphoma. Studies with Anti-Idiotypic Antibodies. In: Proceedings of the Second International Conference on Malignant Lymphoma. Martinus Nishoff Publishing, Boston, Massachusetts, 1984.
5. Thompson JM, Gralow J, Levy R, Miller RA. The Optimal Application of Forward and Ninety-Degree Light Scatter in Flow Cytometry for the Gating of Mononuclear Cells. *Cytometry*, 6: 401-6, 1985.
6. Dubeau LA, Chandler L, Gralow J, Nichols PW, Jones PA. Southern Blot Analysis of DNA Extracted from Formalin-Fixed Pathology Specimens. *Cancer Research*, 46: 2964-9, 1986.
7. Lowder JN, Meeker TC, Campbell M, Garcia CF, Gralow J, Miller RA, Warnke R, Levy R. Studies on B Lymphoid Tumors Treated with Monoclonal Anti-idiotypic Antibodies: Correlation with Clinical Responses. *Blood*, 69 (1): 199-210, 1987.
8. Miller RA, Lowder JN, Gralow J, Meeker T, Levy R. In Vitro Tests that Predict Tumor-Associated Idiotypic Levels in the Serum of Patients with B Cell Lymphomas and Leukemias. *Blood*, 69 (4): 1249-54, 1987.
9. Disis ML, Bernhard H, Gralow JR, Hand SL, Emery SR, Calenoff E, Cheever MA. Immunity to the HER-2/*neu* Oncogenic Protein. In Vaccines Against Virally Induced Cancers, Ciba Foundation Symposium No. 187, John Wiley & Sons, Inc., 198-211, 1994.
10. Bernhard H, Disis ML, Heimfeld S, Hand S, Gralow JR, and Cheever MA. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. *Cancer Research*, 55: 1099 – 1104, 1995.
11. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi, M, and Chen W. Immunity to Oncogenic Proteins. *Imm Rev* 145: 33-59, 1995.
12. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, and Cheever MA. GM-CSF: An Effective Adjuvant for Protein and Peptide Based Vaccines. *Blood*, 88:202-10, 1996.
13. Gralow JR, Anderson BO. Breast Cancer Patient Follow-Up. In Cancer Patient Follow-Up, Johnson, F. and Virgo, K.S. ed., Moseby-Year Book, Inc., 1996.
14. Gralow JR, Livingston RL, Hunt K, Petersdorf S. Oncologic Therapeutics. In Medical Therapeutics, Ramsey P and Larson EB, ed., W.B. Saunders Co., 1996.
15. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA. Peptide Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2/*neu*, an Oncogenic Self-Protein. *J Immunology*, 156:3151-8, 1996.
16. Gralow JR (editor). Finding Your Way to Wellness: A Puget Sound Breast Cancer Information and Resource guide. Peanut Butter Publishing. 1996.
17. Gralow JR. Combining Complementary and Conventional Therapies in Medical Practice: A Medical Oncologist's Perspective. *Northwest Physician*, Winter 1996.

18. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt S, Adamkiewicz BB, Long CA. Dose-Intensive Vinorelbine with Concurrent Granulocyte Colony-Stimulating Factor Support in Paclitaxel-Refractory Metastatic Breast Cancer. *J Clin Oncol* 15: 1395-1400, 1997.
19. Tait DL, Jensen RA, Gralow, J, King, MC, Johnson DH, Holt, JT. Gene Therapy for Breast and Ovarian Cancer with BRCA1. *Breast Disease* 10:89-98, 1998.
20. Disis ML, Pupa SM, Gralow, JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu Protein-specific Antibody Can Be Detected in Patients with Early-stage Breast Cancer. *J Clin Oncol* 15: 3363-3367, 1997.
21. Anderson BO, Austin-Seymour MM, Gralow JR, Moe RE, Byrd DR. A Multidisciplinary Approach to Locoregional Management of the Axilla for Primary Operable Breast Cancer. *Cancer Control* 6:491-499, 1997.
22. Clark JI, Alpaugh RK, von Mehren M, Schultz J, Gralow JR, Cheever MA, Ring DB, Weiner LM. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. *Cancer Immunol Immunother* 44:265-272, 1997.
23. McTiernan A, Kumai C, Bean D, Schwartz R, Ulrich C, Mahloch J, Hastings R, Gralow J, Potter J. Anthropometric and Hormone Effects of an 8-week Exercise-Diet Intervention in Breast Cancer Patients: Results of a Pilot Study. *Cancer Epidemiology, Biomarkers, Prevention* 7:477-481, 1998.
24. Hathaway PB, Mankoff DA, Maravilla KR, Austin-Seymour MM, Gralow JR, Cortese AA, Hayes, CE, Moe RE. The value of combined FDG-PET and magnetic resonance imaging in the evaluation of suspected local-regional breast cancer: preliminary experience. *Radiology* 210: 807-814, 1999.
25. Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingston RB. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: High complete response rate in a phase I-II study in doxorubicin-treated patients. *J Clin Oncol* 17:1407-1412, 1999.
26. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. *Cancer* 85(11):2410-2423, 1999.
27. Gralow, JR. Herceptin for the treatment of metastatic breast cancer. *Curr Practice Med* 2:49-52, 1999.
28. Bowen D, McTiernan A, Burke W, Powers D, Pruski J, Durfy S, Gralow J, Malone K. Participation in breast cancer risk counseling among women with a family history. *Cancer Epidemiol Biomarkers Prev* 8(7):581-585, 1999.
29. Gralow JR (editor). *Finding Your Way to Wellness: A Puget Sound Breast Cancer Information and Resource guide: Second Edition.*..Published by Susan G. Komen Breast Cancer Foundation. 2000.
30. Bellon JR, Lindsley KL, Ellis GK, Gralow JR, Livingston RB, Austin Seymour MM. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. *Int J Radiat Oncol Biol Phys* 48(2):393-397, 2000.
31. Bernhard H, Huseby ES, Hand SL, Lohmann M, Batten WY, Disis ML, Gralow JR, Meyer zum Buschenfelde KH, Ohlen C, Cheever MA. Dendritic cells lose ability to present protein antigen after

stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression. *Immunobiology* 201(5):568-582, 2000.

32. McTiernan A, Gralow J, Talbott L. Breast Fitness: An Optimal Exercise and Health Plan for Reducing your Risk of Breast Cancer. St. Martin's Press, 2000.
33. Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, Gralow JR, Charlop A, Ellis GK, Lindsley KL, Austin-Seymour MM, Funkhouser CP, Livingston RB. [F-18]-Fluorodeoxyglucose (FDG) Positron emission tomography (PET) to detect mediastinal or internal mammary metastases in breast cancer. *J Clin Oncol* 19(15):3516-3523, 2001.
34. Mankoff DA, Peterson LM, Tewson TJ, Link JM, Gralow JR, Graham MM, Krohn KA. [18F]fluoroestradiol radiation dosimetry in human PET studies. *J Nucl Med* 42(4):679-684, 2001.
35. Daling JR, Malone K, Doody DR, Johnson LG, Gralow JR, Porter PL. Relationship of body mass index to tumor markers and survival among young women with invasive ductal breast cancer. *Cancer* 92:720-729, 2001.
36. Gralow JR, Livingston RB. University of Washington high-dose cyclophosphamide, mitoxantrone, and etoposide experience in metastatic breast cancer: Unexpected cardiac toxicity. *J Clin Oncol* 19:3903-3904, 2001.
37. Gralow JR. The role of bisphosphonates as adjuvant therapy for breast cancer. *Curr Oncol Rep* 3:506-515, 2001.
38. Wilkie DJ, Huang HY, Berry DL, Schwartz A, Lin YC, Ko NY, Chen C, Gralow J, Lindsley K, Fitzgibbon D. Cancer symptom control: Feasibility of a tailored, interactive computerized program for patients. *Fam Community Health* 24:48-62, 2001.
39. Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Dunnwald LK, Schubert EK, Lindsley SK, Gralow JR, Austin-Seymour MM, Ellis GK, Livingston RB. Detection of locoregional and distant recurrences in breast cancer patients using FDG PET. *Radiographics* 22:5-17, 2002.
40. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. *J Clin Oncol* 20:3317-3327, 2002
41. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TH, Schubert EK, Tseng J, Livingston RB. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. *J Nucl Med* 43(4):500-9, 2002.
42. Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. *J Clin Oncol* 20 (17):3637-3643, 2002.
43. Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB, Mankoff DA. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. *Acad Radiol* 9(8):913-921, 2002.
44. Gralow JR. Bisphosphonates as adjuvant treatment for breast cancer. *BMJ* 325:1051-1052, 2002.

45. Mankoff D, Dunnwald L, Gralow J, Ellis G, Schubert E, Charlop A, Tseng J, Rinn K, Livingston R. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. *Nucl Med Biol* 29:719-727, 2002.
46. Benz C, Clark G, Conzen S, Dorn R, Fuqua S, Gralow J, Greene G, Heimann R, Hellman S, Lippman M, Rosen N, Weiner L. Consensus statement: Expedition Inspiration Fund for Breast Cancer Research meeting 2002. *Breast Cancer Res Treat* 78:127-131, 2003.
47. Garrison JA, McCune JS, Livingston RB, Linden HM, Gralow JR, Ellis GK, West HL. Myalgias and arthralgias associated with paclitaxel. *Oncology* 17:271-277, 2003.
48. Anderson BO, Braun S, Carlson RW, Gralow JR, Lagios MD, Lehman C, Schwartzmann G, Vargas HI. Overview of breast health care guidelines for countries with limited resources. *Breast J* 9 Suppl 2:S42-S50, 2003.
49. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: Use of aromatase inhibitors in the adjuvant setting. *J Clin Oncol* 21: 2597-2599, 2003.
50. Bartelink H, Benz C, Cleveland D, Dorn R, Gralow J, Gradishar WJ, Grant K, Heimann R, Hellman S, Hudis C, Kerbel R, Lippman M, Lung J, Posner MC, Steeg P, Vestal R, Weichselbaum RR, Zetter B. Expedition Inspiration Fund for Breast Cancer Research Meeting 2003. *Breast Cancer Res Treat* 80:139-144, 2003.
51. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. *J Clin Oncol* 21:4042-4057, 2003.
52. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant therapy. *J Nucl Med* 44:1806-1014, 2003.
53. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM. HER-2 testing in breast cancer using parallel tissue-based methods. *JAMA* 291:1972-1977, 2004.
54. Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, Mankoff DA. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer. *Am J Clin Oncol* 27:407-410, 2004.
55. Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seymour M, Livingston R. Impact of FDG PET on defining the extent of disease and on treatment of patients with recurrence or metastatic breast cancer. *Am J Roentgenol* 183:479-486, 2004.
56. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for

Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004. *J Clin Oncol* 23:619-629, 2005.

57. Pierce LJ, Hutchins LF, Green SR, Lew DL, Gralow JR, Livingston RB, Osborne CK, Albain KS. Sequencing of Tamoxifen and Radiotherapy After Breast-Conserving Surgery in Early-Stage Breast Cancer. *J Clin Oncol* 23:24-29, 2005.
58. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, Barlow WE, Schubert EK, Mankoff DA. Residual tumor uptake of [(99m)Tc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast cancer predicts survival. *Cancer* 103:680-688, 2005.
59. Gralow JR. Optimizing the treatment of metastatic breast cancer. *Breast Ca Res Treat* 89 Suppl 1:S9-15, 2005.
60. Gralow JR. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. *Clin Breast Cancer* 5 Suppl 2:S54-62, 2005.
61. Hudis CA, Vogel CL, Gralow JR, Williams D. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: Effect on hemoglobin and quality of life. *Clin Breast Cancer* 6:132-142, 2005.
62. Gralow JR. Breast Cancer 2004: Progress and promise on the clinical front. *Phys Med* 21 Suppl 1:2, 2006.
63. Ruggiero S, Gralow J, Marx R, Hoff A, Schubert M, Huryn J, Toth B, Damato K, Valero V. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. *J Oncol Practice* 2:7-14, 2006.
64. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment. *J Clin Oncol*, 24:2793-2799, 2006.
65. Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA. Serial 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). *Breast Cancer Res Treat*, 105(1): 87-94, 2007.
66. Gralow JR (editor). *Finding Your Way to Wellness: A Puget Sound Breast Cancer Information and Resource guide: Third Edition*. Published by Susan G. Komen Breast Cancer Foundation. 2007.
67. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ; American Society of Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical Oncology. *J Clin Oncol* 25:146-162, 2007.
68. Gralow JR, Tripathy D. Managing Metastatic Bone Pain: The Role of Bisphosphonates. *J Pain Symptom Manage* 33:462-272, 2007.

69. Moore H, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C, Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. *J Clin Oncol* 25:1677-1682, 2007.
70. Gralow JR. Bone density in breast cancer: When to intervene? *J Clin Oncol* 25(22): 3195-3197, 2007.
71. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B. Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. *Ann Oncol* 19:420-432, 2007.
72. Bowen DJ, Fann JR, Andersen MR, Rhew IC, Gralow JR, Lewis FM, Hunt JR, Palomares M, Moinpour CM, Ankerst DP. Recruiting Patients With Breast Cancer and Their Families to Behavioral Research in the Post-HIPAA Period. *Oncol Nurs Forum* 34(5): 1049-1054, 2007.
73. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 357:2666-76, 2007.
74. Lewis FM, Cochrane BB, Fletcher KA, Zahlis EH, Shands ME, Gralow JR, Wu SM, Schmitz K. Helping her heal: A pilot study of an educational counseling intervention for spouses of women with breast cancer. *Psychooncology* 17:131-7, 2008.
75. Syrjala KL, Abrams JR, Polissar NL, Hansberry J, Robison J, Dupen S, Stillman M, Fredrickson M, Rivkin S, Feldman E, Gralow J, Rieke JW, Raish RJ, Lee DJ, Cleeland CS, Dupen A. Patient training in cancer pain management using integrated print and video materials: A multisite randomized controlled trial. *Pain* 135:175-86, 2008.
76. Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W Jr, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS. Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening: A Report from the American Society of Clinical Oncology. *J Clin Oncol* 26:313-325, 2008.
77. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. *J Clin Oncol* 26:1231-1238, 2008.
78. Gralow JR, Zujewski JA, Winer E. Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. *J Clin Oncol* 26:696-7, 2008.
79. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. *J Clin Oncol* 26:814-9, 2008.

80. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, Gralow J. Major depression after breast cancer: a review of epidemiology and treatment. *Gen Hosp Psychiatry* 30:112-126, 2008.
81. Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. *Clin Breast Cancer* 8:33-7, 2008.
82. Coleman RE, Body JJ, Gralow JR, Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. *Cancer Treat Rev* 34 Suppl 1:S31-42, 2008.
83. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA. Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. *J Clin Oncol* 26:4449-4457, 2008.
84. Bunnell C, Vahdat L, Schwartzberg L, Gralow J, Klimovsky J, Poulart V, Peck R, Thomas E. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. *Clin Breast Cancer* 8:234-41, 2008.
85. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. *J Clin Oncol* 26:4672-8, 2008.
86. Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, Gralow J, Hortobagyi GN, Livingston R. A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. *Clin Breast Cancer* 8:511-515, 2008.
87. Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. *J Clin Oncol* 27:812-826, 2009.
88. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S. Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates. *J Clin Oncol* 27:1564-71, 2009.
89. Koon K, Soldak T, Gralow J. Breast Cancer Advocacy: Changing Perceptions. *Salud Publica de Mexico* 51:323-328, 2009. PMID: 19967289
90. Muss HB, Berry DA, Cirincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant chemotherapy in older women with early-stage breast cancer. *N Engl J Med* 360:2055-2065, 2009. PMID: 19439741

91. Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, Fizazi K. Effects of Denosumab in Patients with Bone Metastases, with and without Previous Bisphosphonate Exposure. *J Bone Miner Res* 25:440-6, 2010. PMID: 19653815
92. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH. NCCN Task Force Report: Bone Health in Cancer Care. *J Natl Compr Canc Netw* 7: Suppl 3:S1-S32, 2009. PMID: 19555589
93. Specht J, Gralow JR. Neoadjuvant chemotherapy for locally advanced breast cancer. *Semin Radiat Oncol* 19:222-228, 2009. PMID: 19732686
94. Jotwani AC, Gralow JR. Early detection of breast cancer: new biomarker tests on the horizon? *Mol Diagn Ther* 13:349-57, 2009. PMID: 19925032
95. Sparano JA, Hortobagyi GN, Gralow JR, Perez EA, Comis RL. Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. *Breast Cancer Res Treat* 119:511-27, 2010. PMID: 19526354
96. Sparano JA, Pisano ED, White JR, Hunt KK, Mamounas EP, Perez EA, Hortobagyi GN, Gralow JR, Comis RL. Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy. *Breast Cancer Res Treat* 120:273-84, 2009. PMID: 20024613
97. Gralow JR. Adjuvant Systemic Therapy: Bisphosphonates. In Diseases of the Breast, 4th edition, Harris JR, Lippman ME, Morrow M, Osborne CK, eds, Lippincott, Williams & Wilkins, 2009.
98. Korde LA, Gralow JR. The Bone Continuum of Cancer: Early to Advanced Stage Disease. *Clin Oncol* December 2009.
99. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol* 11:55-65, 2010. PMID: 20005174
100. Zielinski C, Gralow J, Martin M. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? *Ann Oncol* 2010 23 March 2010, 10.1093/annonc/mdq069. PMID: 20332132
101. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F. Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations. *J Clin Oncol* 28:2114-22, 2010. PMID: 20308661
102. Pippen J, Elias AD, Neubauer M, Stokoe C, Vaughn LG, Wang Y, Orlando M, Shonukan O, Muscato J, O'Shaughnessy JA, Gralow J. A Phase II Trial of Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer Who Have Received Prior Taxane Therapy. *Clin Breast Cancer* 10:148-53, 2010. PMID: 20299319

103. Doot RK, Muzi M, Peterson LM, Schubert EK, Gralow JR, Specht JM, Mankoff DA. Kinetic Analysis of 18F-Fluoride PET Images of Breast Cancer Bone Metastases. *J Nucl Med* 51:521-7, 2010. PMID: 20237040
104. Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. *J Clin Oncol* 28:2418-22, 2010. PMID: 20368559
105. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: Advancing treatment and prevention. *Cancer Treat Rev* 36:615-629, 2010. PMID: 20478658
106. Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston RB, Allison KH, Schubert EK, Mankoff DA. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. *Clin Cancer Res* 16:2803-10, 2010. PMID: 20478658
107. Jensen MP, Chang HY, Lai YH, Syrjala KL, Fann JR, Gralow JR. Pain in Long-Term Breast Cancer Survivors: Frequency, Severity, and Impact. *Pain Med* 11:1099-1106, 2010. PMID: 20545872
108. Korde LA, Gralow JR. Are bisphosphonates ready for the adjuvant setting? *Oncology* 24(6):480-485, 2010. PMID: 20568589
109. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB. HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. *J Clin Oncol* 28:4307-4315, 2010. PMID: 20697084
110. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, Gospodarowicz M, Gralow J, Gupta S, Langer A, Lob-Levyt J, Neal C, Mbewu A, Mired D, Piot P, Reddy KS, Sachs JD, Sarhan M, Seffrin JR. Expansion of cancer care and control in countries of low and middle income: a call to action. *Lancet* 376:1186-1193, 2010. PMID: 20709386
111. Gralow JR. Bisphosphonate risks and benefits: Finding a balance. *J Clin Oncol* 28:4873-4876, 2010. PMID: 20940189
112. Gralow J. Adjuvant Chemotherapy for Breast Cancer: Are Anthracyclines Out? *Community Oncology* 7:14-17, 2010.
113. Albain KS, Carey L, Gradishar WJ, Gralow JR, Lipton A, Rugo H, Tripathy D, Peck S, Abair T, Pegram M. Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. *Clin Breast Cancer* 10:421-39, 2010. PMID: 21147685
114. Korde LA, Gralow JR. Bone Issues in Breast Cancer. *Clin Oncol* 13:1, 2010.
115. Korde L, Gralow JR. Bone Disease in Breast Cancer: The Era of New Targeted Therapies. *Current Breast Cancer Reports* 2:25-31, 2010.

116. Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012. *J Clin Oncol* 29:1014-1021, 2011. PMID: 21220618
117. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, Reinholz MM. C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. *J Clin Oncol* 29:651-659, 2011. PMID: 21245420
118. Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi V, Kurland BF, Schubert EK, Muzi M, Mankoff DA. PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static vs Kinetic Measures of Fluorodeoxyglucose Uptake. *Clin Cancer Res* 17:2400-2409, 2011. PMID: 21364034
119. Harford JB, Otero IV, Anderson BO, Cazap E, Gradishar WJ, Gralow JR, Kane GM, Niëns LM, Porter PL, Reeler AV, Rieger PT, Shockney LD, Shulman LN, Soldak T, Thomas DB, Thompson B, Winchester DP, Zelle SG, Badwe RA. Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative. *Breast* 20:S20-19, 2011. PMID: 21376593
120. El Saghir NS, Adebamowo CA, Anderson BO, Carlson RW, Bird PA, Corbex M, Badwe RA, Bushnaq MA, Eniu A, Gralow JR, Harness JK, Masetti R, Perry F, Samiei M, Thomas DB, Wiafe-Addai B, Cazap E. Breast cancer management in low resource countries (LRCs): Consensus statement from the Breast Health Global Initiative. *Breast* 20:S3-11, 2011. PMID: 21392996
121. Korde L, Gralow JR. Breast cancer therapy and reproduction. In Principles and Practice of Fertility Preservation, Donnez J and Kim SS eds, pp. 62-72, Cambridge University Press, 2011.
122. Koon KP, Gralow JR. Recurrence and second primary cancers. In Cancer rehabilitation and survivorship: Transdisciplinary approaches to personalized care, J.L. Lester & P. Schmitt eds. Pittsburgh, PA: Oncology Nursing Society, 2011.
123. Anderson BO, Gralow JR. Axillary vs sentinel lymph node dissection for invasive breast cancer. *JAMA* 305:2290, 2011. PMID:21642676
124. Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. *Clin Cancer Res* 17:4799-4805, 2011. PMID: 21750198
125. Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). *Breast Cancer Res Treat* 130:993-1002, 2011 PMID: 21766209

126. Rodler E, Korde L, Gralow J. Current Treatment Options in Triple Negative Breast Cancer. *Breast Dis* 32:99-122, 2011. PMID: 21778572
127. Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. *Breast Cancer Res Treat* 130:123-131, 2011. PMID: 21826527
128. Gralow JR, Lipton A, Stopeck AT. How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer? *J Clin Oncol* 29:3591-35922, 2011. PMID: 21844502
129. Korde LA, Gralow JR. Can We Predict Who's at Risk for Developing Bone Metastases in Breast Cancer? *J Clin Oncol* 29:3600-3603, 2011. PMID: 21859994
130. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer. *J Clin Oncol* 29:4491-4491, 2011. PMID: 22042958
131. Shulman L, Gralow J, Krakauer E, Anderson BO, Porter P, Gospodarowicz M, Feldman S, Rodriguez-Galindo C, Frazier L, Lehmann L. Core elements for provision of cancer care and control in low and middle income countries. In Closing the Cancer Divide: A Blueprint to Expand Access in Low and Middle Income Countries. Knaul FM, Frenk, J, Shulman L (eds) for the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries. Harvard Global Equity Initiative, Boston, MA, October 2011.
132. Knaul FM, Bhadelia A, Gralow J, Langer A. Innovative delivery of cancer care and control in low-resource scenarios. In Closing the Cancer Divide: A Blueprint to Expand Access in Low and Middle Income Countries. Knaul FM, Frenk, J, Shulman L (eds) for the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries. Harvard Global Equity Initiative, Boston, MA, October 2011.
133. Quick J, Konduri N, Gralow J. Access to affordable medicines, vaccines, and health technologies for cancer: overcoming price and non-price barriers to access. In Closing the Cancer Divide: A Blueprint to Expand Access in Low and Middle Income Countries. Knaul FM, Frenk, J, Shulman L (eds) for the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries. Harvard Global Equity Initiative, Boston, MA, October 2011.
134. Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B. Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. *J Natl Cancer Inst* 104:159-62, 2012. PMID:22138096
135. Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL 3rd, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Phase II Trial of Simple Oral Therapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer: SWOG S0430. *Oncologist* 17:179-87, 2012. PMID:22267853
136. Jensen MP, Gralow JR, Braden A, Gertz KJ, Fann JR, Syrjala KL. Hypnosis for symptom management in women with breast cancer: a pilot study. *Int J Clin Exp Hypn* 60:135-159, 2012. PMID:22443523

137. Knaul FM, Shulman LN, Gralow J, Quick J, Bhadelia A, Frenk J. Improving pathology for better cancer care and control in countries of low and middle income. *Lancet* 379:2052, 2012. PMID:22656884
138. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE Jr, Swain SM, Costantino JP, Mamounas EP, Wolmark N. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. *Lancet Oncol* 13(7):734-42, 2012. PMID: 22704583
139. Javid SH, Unger JM, Gralow JR, Moinpour CM, Wozniak AJ, Goodwin JW, Lara PN Jr, Williams PA, Hutchins LF, Gotay CC, Albain KS. A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316). *Oncologist* 17:1180-1190, 2012. PMID: 22723506
140. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. *N Engl J Med* 367(5):435-44, 2012. PMID: 22853014
141. Knaul FM, Bhadelia A, Gralow J, Arreola-Ornelas H, Langer A, Frenk J. Meeting the emerging challenge of breast and cervical cancer in low- and middle-income countries. *Int J Gynaecol Obstet* 119: Suppl 1:S85-88, 2012. PMID: 22883910
142. Blum JL, Barrios CH, Feldman N, Verma S, McKenna EF, Lee LF, Scotto N, Gralow J. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. *Breast Cancer Res Treat* 136:777-788, 2012. PMID: 23104222
143. Gralow J. Can bone-targeted therapy reduce recurrence and improve survival in early-stage breast cancer? *Oncology (Williston Park)* 26:969-70, 2012. PMID:23176010
144. Knaul FM, Gralow JR, Atun R, Bhadelia A (eds). *Closing the Cancer Divide: An Equity Imperative*. Harvard University Press. Boston, MA, 2012.
145. Zirpoli GR, Brennan PM, Hong CC, McCann SE, Ciupak G, Davis W, Unger JM, Budd GT, Hershman DL, Moore HC, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Ambrosone CB. Supplement use during an intergroup clinical trial for breast cancer (S0221). *Breast Cancer Res Treat* 137:903-13, 2013. PMID:23306462
146. Koon KP, Lehman CD, Gralow JR. The importance of survivors and partners in improving breast cancer outcomes in Uganda. *Breast* 22:138-141, 2013. PMID:23313061
147. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS. Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial. *Clin Cancer Res* 19(5):1281-1289, 2013. PMID:23340303
148. Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM. Impact of

PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial. *J Clin Oncol* 31(17):2115-2, 2013. PMID: 23650412

149. Reece JC, Chan YF, Herbert J, Gralow J, Fann JR. Course of depression, mental health service utilization and treatment preferences in women receiving chemotherapy for breast cancer. *Gen Hosp Psychiatry* 35:376-381, 2013. PMID: 23642440
150. Carlson JJ, Thariani R, Roth J, Gralow J, Henry NL, Esmail L, Deverka P, Ramsey SD, Baker L, Veenstra DL. Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics. *Med Decis Making* 33(4):463-71, 2013. PMID: 23635833
151. Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831. *Cancer* 119(15):2675-82, 2013. PMID: 23744760
152. Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray S, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM. Frequent Antibiotic Use and Second Breast Cancer Events. *Cancer Epidemiol Biomarkers Prev* 22:1588-1599, 2013. PMID: 23833124
153. Wang H, Yumul R, Cao H, Ran L, Fan X, Richter M, Epstein F, Gralow J, Zubieta C, Fender P, Lieber A. Structural and functional studies on the interaction of adenovirus fiber knob domains and desmoglein 2. *J Virol* 87:11346-11362, 2013. PMID: 23946456
154. Dueck AC, Reinholz MM, Geiger XJ, Tenner KS, Ballman KV, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris L, Ingle JN, Lingle W, Perez EA. Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831. *Clin Cancer Res* 19:5798-5807, 2013. PMID: 23965903
155. Cleary J, Ddungu H, Distelhorst SR, Ripamonti C, Rodin GM, Bushnaq MA, Clegg-Lampsey JN, Connor SR, Diwani MB, Eniu A, Harford JB, Kumar S, Rajagopal MR, Thompson B, Gralow JR, Anderson BO. Supportive and palliative care for metastatic breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. *Breast* 22:616-627, 2013. PMID: 23972474
156. Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, Bevilacqua JL, de Azambuja E, El Saghir NS, Kaur R, McTiernan A, Partridge AH, Rowland JH, Singh-Carlson S, Vargo MM, Thompson B, Anderson BO. Supportive care after curative treatment for breast cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. *Breast* 22:606-15, 2013. PMID: 24007941
157. Cardoso F, Bese N, Distelhorst SR, Bevilacqua JL, Ginsburg O, Grunberg SM, Gralla RJ, Steyn A, Pagni O, Partridge AH, Knaul FM, Aapro MS, Andersen BL, Thompson B, Gralow JR, Anderson BO. Supportive care during treatment for breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. *Breast* 22:593-605, 2013. PMID: 24001709

158. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S, Van Poznak CH. NCCN Task Force Report: Bone Health In Cancer Care. *J Natl Compr Canc Netw Suppl* 3:S1-50, 2013. PMID:23997241
159. Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. *Pharmacogenomics J* 14:241-247, 2013. PMID: 23999597
160. Thariani R, Henry NL, Ramsey SD, Blough DK, Barlow B, Gralow JR, Veenstra DL. Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. *J Comp Eff Res* 2:325-34, 2013. PMID: 24236631
161. Gralow JR, Barlow WE, Lew D, Dammann K, Somlo G, Rinn KJ, Vogel SJ, Wong L, Livingston RB, Hortobagyi GN. A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. *Breast Cancer Res Treat* 143:351-8, 2014. PMID: 24352574
162. Wirtz HS, Boudreau DM, Gralow JR, Barlow WE, Gray S, Bowles EJ, Buist DS. Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors. *Breast Cancer Res Treat* 143:541-550, 2014. PMID: 24407530
163. Goodwin PJ, Segal RJ, Vallis M, Ligibel JA, Pond GR, Robidoux A, Blackburn GL, Findlay B, Gralow JR, Mukherjee S, Levine M, Pritchard KI. Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial. *J Clin Oncol* 32:2231-2239, 2014. PMID: 24934783
164. Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Yoo B, Brammer MG, Vogel CL. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. *Cancer* 120:2657-64, 2014. PMID: 24930388
165. Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM. Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. *Pharmacoepidemiol Drug Saf* 24:75-85, 2014. PMID: 24923811
166. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. *J Clin Oncol* 32:3483-3489, 2014. PMID: 24888818
167. Henry LN, Hayes DF, Ramsey SD, Hortobagyi GN, Barlow WE, Gralow JR. Promoting quality and evidence-based care in early-stage breast cancer follow-up. *J Natl Cancer Inst* 106, 2014. PMID: 24627271
168. Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilias G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. *Br J Cancer* 111:1065-71, 2014. PMID: 25117817

169. Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. *Br J Cancer* 111:1241-8, 2014. PMID: 25117820
170. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. *J Clin Oncol* 32:3744-52, 2014. PMID: 25332249
171. Calip GS, Malone KE, Gralow JR, Stergachis A, Hubbard RA, Boudreau DM. Metabolic syndrome and outcomes following early-stage breast cancer. *Breast Cancer Res Treat* 148:363-77, 2014. PMID: 25301086
172. Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 32:3307-29, 2014. PMID: 25185096
173. Ramsey SD, Henry NL, Gralow JR, Mirick DK, Barlow W, Etzioni R, Mummy D, Thariani R, Veenstra DL. Tumor marker usage and medical care costs among older early-stage breast cancer survivors. *J Clin Oncol* 33:149-55, 2015. PMID: 25332254
174. Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. *J Clin Oncol* 33:58-64, 2015. PMID: 25422488
175. Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM. Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. *J Clin Oncol* 33(7): 701-8, 2015. PMID:25605861
176. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med* 372(10):923-32, 2015. PMID: 25738668
177. Distelhorst SR, Cleary JF, Ganz PA, Bese N, Camacho-Rodriguez R, Cardoso F, Ddungu H, Gralow JR, Yip CH, Anderson BO; on behalf of the Breast Health Global Initiative Global Summit on Supportive Care; Quality of Life Consensus Panel Members. Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014. *Lancet Oncol* 16(3):e137-e147, 2015. PMID: 25752564

178. Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade JL 3rd, Meyskens FL, Moinpour CM. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. *J Clin Oncol* 10;33(17):1910-7, 2015. PMID: 25940724
179. Jatoi A, Muss H, Allred JB, Cohen HJ, Ballman K, Hopkins JO, Gajra A, Lafky J, Wolff A, Kottschade L, Gralow J, Hurria A. Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301). *Psychooncology* 25:441-446, 2015 PMID: 25994447
180. Jia N, Cormack FC, Xie B, Shiue Z, Najafian B, Gralow JR. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. *BMC Cancer* 15:535, 2015. PMID: 26197890
181. Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet* 386:1353-61, 2015. PMID: 26211824
182. Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC, Jamshidian F, Cherbavaz D, Yoshizawa C, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann YW, Ballman KV. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. *Breast Cancer Res* 17:133, 2015. PMID: 26429296
183. Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL. Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. *JAMA Oncol* 1:137-139, 2016. PMID: 26468994
184. Lehman CD, Lee JM, DeMartini WB, Hippe DS, Rendi MH, Kalish G, Porter P, Gralow J, Partridge SC. Screening MRI in Women With a Personal History of Breast Cancer. *J Natl Cancer Inst.* 108(3), 2016. PMID: 26744477
185. Lichtman SM, Cirrincione CT, Hurria A, Jatoi A, Theodoulou M, Wolff AC, Gralow J, Morganstern DE, Magrinat G, Cohen HJ, Muss HB. Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. *J Clin Oncol* 34(7):699-705, 2016. PMID: 26755551
186. Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Stychor S, Kiesel B, Linden HM, Thompson JA, Swisher EM, Chai X, Shepherd S, Giranda VL, Specht J. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. *Clin Cancer Res* 22:2855-2864, 2016. PMID: 26801247
187. Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. *Br J Clin Pharmacol* 81:1134-1141, 2016. PMID: 26859101

188. Chang HY, Jotwani AC, Lai YH, Jensen MP, Syrjala KL, Fann JR, Gralow J. Hot flashes in breast cancer survivors: Frequency, severity and impact. *Breast* 27:116-121, 2016. PMID: 27065357
189. Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. *N Engl J Med* 375(3):209-19, 2016. PMID: 27264120
190. Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. *Breast Cancer Res Treat* 158(3):485-95, 2016. PMID: 27393622
191. Mendoza ME, Capafons A, Gralow JR, Syrjala KL, Suárez-Rodríguez JM, Fann JR, Jensen MP. Randomized controlled trial of the Valencia model of waking hypnosis plus CBT for pain, fatigue, and sleep management in patients with cancer and cancer survivors. *Psychooncology* 26(11):1832-38, 2017. PMID: 27467589
192. Moinpour CM, Donaldson GW, Davis KM, Potosky AL, Jensen RE, Gralow JR, Back AL, Hwang JJ, Yoon J, Bernard DL, Loeffler DR, Rothrock NE, Hays RD, Reeve BB, Smith AW, Hahn EA, Cella D. The challenge of measuring intra-individual change in fatigue during cancer treatment. *Qual Life Res* 26: 259-271, 2017. PMID: 27469506
193. Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, Sarker M, Huong TT, Allemani C, Dvaladze A, Gralow J, Yeates K, Taylor C, Oomman N, Krishnan S, Sullivan R, Kombe D, Blas MM, Parham G, Kassami N, Conteh L. The global burden of women's cancers: a grand challenge in global health. *Lancet* 389: 847-860, 2017. PMID: 27814965
194. Gadi VK, Gralow JR. Breast Cancer Outlook for 2017: Keeping the Accelerator to the Floor. *Oncology* 30 (12 Suppl 2):1-2, 2016. PMID: 27933601
195. Van Poznak CH, Darke A, Moinpour CM, Bagramian RA, Schubert MM, Gralow JR, Wade JL 3rd, Unger JM. Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702. *Support Care Cancer* 25:1191-1199, 2017. PMID: 27928641
196. Wirtz HS, Calip GS, Buist DS, Gralow JR, Barlow WE, Gray S, Boudreau DM. Evidence for Detection Bias by Medication Use in a Cohort Study of Breast Cancer Survivors. *Am J Epidemiol* 185:661-672, 2017. PMID: 28338879
197. Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E. Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. *J Clin Oncol* 35:1421-1429, 2017. PMID: 28375706
198. Gingras I, Holmes E, De Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart MJ,

Azim HA Jr. Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis from the ALTTO Trial. *J Natl Cancer Inst* 109(8), 2017. PMID: 28376188

199. Powles TJ, Paterson AHG, Gralow JR. Optimal Use of Adjuvant Bisphosphonates and Breast Cancer. *J Clin Oncol* 35:2719-2720, 2017. PMID: 28654362
200. Spraggs CF, Parham LR, Briley LP, Warren L, Williams LS, Fraser DJ, Jiang Z, Aziz Z, Ahmed S, Demetriou G, Mehta A, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow J, Zujewski JA, Crescenzo R, Armour A, Perez E, Piccart M. Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. *Pharmacogenomics J* 18(3):480-486, 2017. PMID: 28786423
201. Duggan C, Dvaladze AL, Tsu V, Jeronimo J, Constant TKH, Romanoff A, Scheel JR, Patel S, Gralow JR, Anderson BO. Resource-stratified implementation of a community-based breast cancer management programme in Peru. *Lancet Oncology* 18(10):e607-e617, 2017. PMID: 28971827
202. Chang AE, Wu QV, Jenkins IC, Specht JM, Gadi VK, Gralow JR, Salazar LG, Kurland BF, Linden HM. Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. *Clin Breast Cancer* 18(1):e143-e149, 2018. PMID: 29174203
203. Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, Hershman D, Albain KS, Hayes DF, Moore HC, Hobday TJ, Stewart JA, Rizvi A, Isaacs C, Salim M, Gralow JR, Hortobagyi GN, Livingston RB, Kroetz DL, Ambrosone CB. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. *Pharmacogenet Genomics* 28(2):49-55, 2018. PMID: 29278617
204. Lemieux J, Brundage MD, Parulekar WR, Goss PE, Ingle JN, Pritchard KI, Celano P, Muss H, Gralow J, Strasser-Weippl K, Whelan K, Tu D, Whelan TJ. Quality of Life from Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. *J Clin Oncol* 36(6):563-571, 2018. PMID: 29328860
205. Cho E, Wu Q, Rubinstein L, Linden H, Gralow J, Specht J, Gadi V, Ellis G. Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab-paclitaxel for high-risk early-stage breast cancer. *Breast J* 24(4):610-614, 2018. PMID: 29532546
206. Zirpoli GR, McCann SE, Sucheston-Campbell LE, Hershman DL, Ciupak G, Davis W, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS, Ambrosone CB. Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study. *J Natl Cancer Inst* 109(12), 2017. PMID: 29546345
207. Pelekanou V, Barlow WE, Nahleh Z, Wasserman B, Lo YC, von Wahlde MK, Hayes DF, Hortobagyi GN, Gralow JR, Tripathy D, Porter PL, Szekely B, Hatzis C, Rimm DL, Pusztai L. Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial. *Mol Cancer Ther* 17:1324-1331, 2018. PMID: 29588392

208. Peterson LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, Shields A, Montgomery S, Linden HM, Gralow JR, Gadi VK, Muzi M, Kinahan PE, Mankoff DA, Specht JM. Prospective study of serial 18F-FDG PET and 18F-fluoride (18F-NaF) PET to predict time to skeletal related events, time-to-progression, and survival in patients with bone-dominant metastatic breast cancer. *J Nucl Med* 59(12):1823-1830, 2018. PMID: 29748233
209. Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J, Cardoso MJ, Peccatori F, Paonessa D, Benares A, Sakurai N, Beishon M, Barker SJ, Mayer M. Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015). *Breast* 39:131-138, 2018. PMID: 9679849
210. Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, Dakhil SR, Minasian LM, Wade JL 3rd, Fisch MJ, Henry NL, Hershman DL. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). *Breast Cancer Res Treat* 172(3):603-610, 2018. PMID: 30159789
211. Scheel JR, Molina Y, Anderson BO, Patrick DL, Nakigudde G, Gralow JR, Lehman CD, Thompson B. Breast Cancer Beliefs as Potential Targets for Breast Cancer Awareness Efforts to Decrease Late-Stage Presentation in Uganda. *J Glob Oncol* Sept (4):1-9, 2018. PMID: 30241166
212. Greenlee H, Lew DL, Hershman DL, Newman VA, Hansen L, Hartman SJ, Korner J, Shi Z, Sardo Molmenti CL, Sayegh A, Fehrenbacher L, Lo S, Klemp J, Rinn K, Robertson JM, Unger J, Gralow J, Albain K, Krouse R, Fabian C. Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008). *Obesity (Silver Spring)* 26(10):1539-1549, 2018. PMID: 30272836
213. Langer SL, Romano JM, Todd M, Strauman TJ, Keefe FJ, Syrjala KL, Bricker JB, Ghosh N, Burns JW, Bolger N, Puleo BK, Gralow JR, Shankaran V, Westbrook K, Zafar SY, Porter LS. Links Between Communication and Relationship Satisfaction Among Patients with Cancer and Their Spouses: Results of a Fourteen-Day Smartphone-Based Ecological Momentary Assessment Study. *Front Psychol* 9:1843, 2018. PMID: 30364167
214. Mongiovi JM, Zirpoli GR, Cannioto R, Sucheston-Campbell LE, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Thomas Budd G, Albain KS, Ambrosone CB, McCann SE. Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). *Breast Cancer Res* 20(1):146, 2018. PMID: 30486865
215. Dizon DS, Sedrak MS, Lewis MA, Cook E, Fisch MJ, Klemp JR, Sommers J, Ciccarella A, Gralow J, Lawton W, Nichols C; SWOG Digital Engagement Committee. Incorporating Digital Tools to Improve Clinical Trial Infrastructure: A White Paper From the Digital Engagement Committee of SWOG. *JCO Clin Cancer Inform* (2):1-8, 2018. PMID: 30652537.
216. Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, Dakhil SR, Minasian LM, Wade JL 3rd, Fisch MJ, Henry NL, Hershman DL. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). *Breast Cancer Res Treat* 172(3):603-610, 2018. PMID: 30159789
217. Loehrer PJ, Rosen B, Orang'o EO, Gralow JR. Capacity building in sub-Saharan Africa: Models of Care. *The Lancet* 6:S17-18, 2018. [https://doi.org/10.1016/S2214-109X\(18\)30090-1](https://doi.org/10.1016/S2214-109X(18)30090-1)

218. Peterson LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, Shields A, Montgomery S, Linden HM, Gralow J, Gadi VK, Muzi M, Kinahan P, Mankoff D, Specht JM. Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer. *J Nucl Med* 59(12):1823-1830, 2018. PMID: 29748233
219. Scheel JR, Parker S, Hippe DS, Patrick DL, Nakigudde G, Anderson BO, Gralow JR, Thompson B, Molina Y. Role of Family Obligation Stress on Ugandan Women's Participation in Preventive Breast Health. *Oncologist* 24(5):624-631, 2019. PMID: 30072390
220. Al-Sukhun S, Temin S, Chavez-MacGregor M, Denduluri N, Oliver TK, Pyle D, Shah MA, Gralow J. ASCO Resource-Stratified Guidelines: Methods and Opportunities. *J Glob Oncol* (4):1-8, 2018. PMID: 30110223
221. Hurria A, Soto-Perez-de-Celis E, Allred JB, Cohen HJ, Arsenyan A, Ballman K, Le-Rademacher J, Jatoi A, Filo J, Mandelblatt J, Lafky JM, Kimmick G, Klepin HD, Freedman RA, Burstein H, Gralow J, Wolff AC, Magrinat G, Barginear M, Muss H. Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. *J Am Geriatr Soc* 67:920-927, 2019. PMID: 30146695
222. Symonds L, Linden H, Gadi V, Korde L, Rodler E, Gralow J, Redman M, Baker K, Wu QV, Jenkins I, Kurland B, Garrison M, Smith J, Anderson J, Van Haelst C; Specht J. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. *Clin Breast Cancer* 19(2):e283-e296, 2019. PMID: 30737173
223. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. *J Natl Cancer Inst* 111: 210-213, 2019. PMID: 30371800
224. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Linden HH, Livingston RB, Hortobagyi GN. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. *N Engl J Med* 380(13):1226-1234, 2019. PMID: 30917258
225. Mrugala MM, Kim B, Sharma A, Johnson N, Graham C, Kurland BF, Gralow J. Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer. *Clin Breast Cancer* 19(5):311-316, 2019. PMID: 31175053
226. Muss HB, Polley MC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey L. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. *J Clin Oncol* 37(26):2338-2348, 2019. PMID: 31339827

227. Paoletti C, Miao J, Dolce EM, Darga EP, Repollet MI, Doyle GV, Gralow JR, Hortobagyi GN, Smerage JB, Barlow WE, Hayes DF. Circulating Tumor Cell Clusters in Metastatic Breast Cancer Patients: a SWOG S0500 Translational Medicine Study. *Clin Cancer Res* 25(20):6089-6097, 2019. PMID: 31358544
228. Sulakvelidze N, Burdick B, Kaklamani V, Tilton K, Baker K, Kim J, Javid S, Gralow JR. Evaluating the Effect of a Video Education Curriculum for First Time Breast Cancer Patients: a Prospective RCT Feasibility Study. *J Cancer Educ* 34:1234-1240, 2019. PMID: 31359374
229. Gralow JR, Barlow WE, Paterson AHG, Miao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. *J Natl Cancer Inst* 112(7):698-707, 2020. PMID: 31693129
230. Ambrosone CB, Zirpoli GR, Hutson AD, McCann WE, McCann SE, Barlow WE, Kelly KM, Cannioto R, Sucheston-Campbell LE, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). *J Clin Oncol* 38(8): 804-814, 2020. PMID: 31855498
231. Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, Whelan TJ, Davidson NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, Gralow JR, Hortobagyi GN, Hayes DF, Albain KS. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients with Node-Positive Breast Cancer. *JAMA Oncol* 6(4): 505-511, 2020. PMID: 31917424
232. Kizub DA, Zujewski J, Gralow JR, Ndoh K, Soko U, Dvaladze AL. Patient Advocacy Approaches to Improving Care for Breast and Cervical Cancer in East and Southern Africa. *JCO Global Oncol* 6:49-55, 2020. PMID: 32031438
233. El Saghir NS, Anderson BO, Gralow J, Lopes G, Shulman LN, Moukadem HA, Yu PP, Hortobagyi G. Impact of Merit-Based Immigration Policies on Brain Drain From Low- and Middle-Income Countries. *JCO Glob Oncol* 6:185-189, 2020. PMID: 32023124
234. Goodwin PJ, Segal RJ, Vallis M, Ligibel JA, Pond GR, Robidoux A, Findlay B, Gralow JR, Mukherjee SD, Levine M, Pritchard KI. The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer. *NPJ Breast Cancer* 6:6, 2020. PMID: 32133391
235. Hunter N, Dempsey N, Tbaishat F, Jahanzeb M, Al-Sukhun S, Gralow JR. Resource-Stratified Guideline-Based Cancer Care Should Be a Priority: Historical Context and Examples of Success. *Am Soc Clin Oncol Educ Book* 40:1-10, 2020. PMID: 32223670
236. Cannioto RA, Hutson A, Dighe S, McCann W, McCann SE, Zirpoli GR, Barlow W, Kelly KM, DeNysschen CA, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Budd GT, Ambrosone CB. Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival. *J Natl Cancer Inst* 113(1):54-63, 2021. PMID: 32239145

237. Dvaladze A, Kizub DA, Cabanes A, Nakigudde G, Aguilar B, Zujewski JA, Duggan C, Anderson BO, Pritam Singh RK, Gralow JR. Breast cancer patient advocacy: A qualitative study of the challenges and opportunities for civil society organizations in low-income and middle-income countries. *Cancer* 126 Suppl 10:2439-2447, 2020. PMID: 32348570
238. Mutebi M, Anderson BO, Duggan C, Adebamowo C, Agarwal G, Ali Z, Bird P, Bourque JM, DeBoer R, Gebrim LH, Masetti R, Masood S, Menon M, Nakigudde G, Ng'ang'a A, Niyonzima N, Rositch AF, Unger-Saldaña K, Villarreal-Garza C, Dvaladze A, El Saghir NS, Gralow JR, Eniu A. Breast cancer treatment: A phased approach to implementation. *Cancer* 126 Suppl 10:2365-2378, 2020. PMID: 32348571
239. Duggan C, Dvaladze A, Rositch AF, Ginsburg O, Yip CH, Horton S, Camacho Rodriguez R, Eniu A, Mutebi M, Bourque JM, Masood S, Unger-Saldaña K, Cabanes A, Carlson RW, Gralow JR, Anderson BO. The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource-Stratified Phased Implementation: Methods and overview. *Cancer* 126 Suppl 10:2339-2352, 2020. PMID: 32348573
240. Hershman DL, Unger JM, Hillyer GC, Moseley A, Arnold KB, Dakhil SR, Esparaz BT, Kuan MC, Graham ML 2nd, Lackowski DM, Edenfield WJ, Dayao ZR, Henry NL, Gralow JR, Ramsey SD, Neugut AI. Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women with Early-Stage Breast Cancer: SWOG S1105. *J Clin Oncol* 38(19):2122-2129, 2020. PMID: 32369401
241. Peterson LM, Kurland BF, Yan F, Novakova-Jiresova A, Gadi VK, Specht JM, Gralow JR, Schubert EK, Link JM, Krohn KA, Eary JF, Mankoff DA, Linden HM. 18F-Fluoroestradiol (18F-FES)-PET imaging in a Phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2-metastatic breast cancer. *J Nucl Med* 62(2):184-190, 2021. PMID: 32591490
242. Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, Ingle JN, Falkson CI, Barlow WE, Hortobagyi GN, Gralow JR. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). *Support Care Cancer* 29(5):2509-2517, 2021. PMID: 32929540
243. Gralow JR, Asirwa FC, Bhatt AS, Bourlon MT, Chu Q, Eniu AE, Loehrer PJ, Lopes G, Shulman LN, Close J, Von Roenn J, Tibbits M, Pyle D. Recommendations from the American Society of Clinical Oncology (ASCO) Academic Global Oncology Task Force. *JCO Glob Oncol* 6:1666-1673, 2020. PMID: 33151772
244. Schoenherr RM, Voytovich UJ, Whiteaker JR, Gadi VK, Gralow JR, Paulovich AG. Quantification of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Protein Expression in Bone Biopsies by Targeted Mass Spectrometry without Acid Decalcification. *Clin Chem* 66(11):1459-1461, 2020. PMID: 33106847
245. Van Poznak CH, Unger JM, Darke AK, Moinpour C, Bagramian RA, Schubert MM, Hansen LK, Floyd JD, Dakhil SR, Lew DL, Wade JL 3rd, Fisch MJ, Henry NL, Hershman DL, Gralow J. Association of Osteonecrosis of the Jaw with Zoledronic Acid Treatment for Bone Metastases in Patients with Cancer. *JAMA Oncol* 7(2):246-254, 2021. PMID: 33331905
246. Menon MP, Niyonzima N, Gralow J, Orem J. Breast Cancer Clinical Trials: The Landscape at the Uganda Cancer Institute and Lessons Learned. *JCO Glob Oncol* 7:127-132, 2021. PMID: 33449804

247. Symonds L, Natarajan P, Cheng RK, Lam DL, Kilgore M, Kim J, Calhoun K, Minami E, Gralow JR. When cardiomyopathy, cancer, and COVID-19 collide: A case report. *Breast J*. 27(4):384-386, 2021. PMID: 33527538
248. Trapani D, Yves Douillard J, Winer EP, Burstein H, Anne Carey L, Cortes J, Lopes G, Gralow JR, Gradishar WJ, Magrini N, Curigliano G, Ilbawi AM. The global landscape of treatment standards for breast cancer. *J Natl Cancer Inst*. 113(9):1143-1155, 2021. PMID: 33502535
249. Yung RL, Gralow JR. Time to Focus on Breast Cancer in Young Adults. *JCO Oncol Pract* 17(6):314-316, 2021. PMID: 33534625
250. Hershman DL, Neugut AI, Moseley A, Arnold KB, Gralow JR, Henry NL, Hillyer GC, Ramsey SD, Unger JM. Patient Reported Outcomes and Long-Term Non-Adherence to Aromatase Inhibitors. *J Natl Cancer Inst* 113(8):989-996, 2021. PMID: 33629114
251. Antone N, Kizub D, Gralow J, Zujewski JA, Dvaladze A. Advancing Breast Cancer Advocacy in Eastern Europe and Central Asia: Findings From Women's Empowerment Cancer Advocacy Network (WE CAN) Summits. *JCO Glob Oncol* 7:585-592, 2021. PMID: 33891477
252. Paoletti C, Barlow WE, Cobain EF, Bergqvist M, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma P, Godwin AK, Thompson AM, Hayes DF, Rae JM. Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial. *Clin Cancer Res* 27(22):6115-6123, 2021. PMID: 34521624
253. Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ Jr, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. *J Clin Oncol* 39(35):3938-3958, 2021. PMID: 34324366
254. Symonds L, Jenkins I, Linden HM, Kurland B, Gralow JR, Gadi VVK, Ellis GK, Wu Q, Rodler E, Chalasani P, Chai X, Riedel J, Scca Network Investigators, Stopeck A, Brown-Glaberman U, Specht JM. A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer. *Clin Breast Cancer* S1526-8209(21)00137-3, 2021. PMID: 34158245
255. Mileham KF, Bruinooge SS, Aggarwal C, Patrick AL, Davis C, Mesenhowski DJ, Spira A, Clayton EJ, Waterhouse D, Moore S, Jazieh AR, Chen RC, Kaltenbaugh M, Williams JH, Gralow JR, Schilsky RL, Garrett-Mayer E. Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. *JCO Oncol Pract* Oct 25:OP2100394, 2021. Online ahead of print. PMID: 34694907
256. Baek G, Jung L, Duong A, Gralow J. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype. *J Oncol Pharm Pract* 28(3):710-716, 2022. PMID: 34761708

257. Moore HCF, Barlow WE, Somlo G, Gralow JR, Schott AF, Hayes DF, Kuhn P, Hicks JB, Welter L, Dy PA, Yeon CH, Conlin AK, Balcueva E, Lew DL, Tripathy D, Puztai L, Hortobagyi GN. A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222. *Clin Cancer Res* 28(4):611-617, 2022. PMID: 34844978
258. Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Harbeck N. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. *J Clin Oncol* 40(5):438-448, 2022. PMID: 34890214
259. Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Daniel F. Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee E-S, Pierga J-Y, Bermejo B, Ramos-Vazquez M, Jung K-H, Ferrero J-M, Schott SF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Puztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. *N Engl J Med* 385(25):2336-2347, 2021. PMID: 34914339
260. Langer SL, Romano JM, Keefe F, Baucom DH, Strauman T, Syrjala KL, Bolger N, Burns J, Bricker JB, Todd M, Baucom BRW, Fischer MS, Ghosh N, Gralow J, Shankaran V, Zafar SY, Westbrook K, Leo K, Ramos K, Weber DM, Porter LS. Couple Communication in Cancer: Protocol for a Multi-Method Examination. *Front Psychol* 12:769407, 2022. PMID: 35222142
261. Sullivan R, Lewison G, Torode J, Kingham PT, Brennan M, Shulman LN, Lawler M, Aggarwal A, Gralow J. Cancer research collaboration between the UK and the USA: reflections on the 2021 G20 Summit announcement. *Lancet Oncol* 23(4):460-462, 2022. PMID: 35358453
262. Wilkie DJ, Schwartz A, Liao WC, Fullwood D, Wu Y, Wallace Farquharson T, Yao Y, & Gralow JR. Reduced Cancer-Related Fatigue After Tablet-based Exercise Education for Patients. *Cancer Control* 29:1-11, 2022. PMID: 35414203
263. Kizub D, Manner CK, Graef K, Abubakar B, Orem J, Odedina F, Adeyeye MC, Nakigudde G, Ayalew K, Kalidas C, Lysterly HK, Norman T, Fashoyin-Aje L, Freedman J, Dent J, Cance B, Gralow J. Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials-Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop. *JCO Glob Oncol* 8:e2200117, June 2022. Online ahead of print. PMID: 35714309
264. Oyer RA, Hurley P, Boehmer L, Bruinooge SS, Levit K, Barrett N, Benson A, Bernick LA, Byatt L, Charlot M, Crews J, DeLeon K, Fashoyin-Aje L, Garrett-Mayer E, Gralow JR, Green S, Guerra CE, Hamroun L, Hardy CM, Hempstead B, Jeames S, Mann M, Matin K, McCaskill-Stevens W, Merrill J, Nowakowski GS, Patel MI, Pressman A, Ramirez AG, Segura J, Segarra-Vasquez B, Hanley Williams J, Williams JE Jr, Winkfield KM, Yang ES, Zwicker V, Pierce LJ. Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. *J Clin Oncol* 40(19):2163-2171, 2022. PMID: 35588469

265. Arnold M, Morgan E, Rungay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. *Breast* 66:15-23, 2022. PubMed PMID: 36084384
266. Mutebi M, Lewison G, Aggarwal A, Alatisie OI, Booth C, Cira M, Grover S, Ginsburg O, Gralow J, Gueye S, Kithaka B, Kingham TP, Kochbati L, Moodley J, Mohammed SI, Mutombo A, Ndlovu N, Ntizimira C, Parham GP, Walter F, Parkes J, Shamely D, Hammad N, Seeley J, Torode J, Sullivan R, Vanderpuye V. Cancer research across Africa: a comparative bibliometric analysis. *BMJ Glob Health* 7(11):e009849, 2022. PMID: 36356985
267. Bergqvist M, Nordmark A, Williams A, Paoletti C, Barlow W, Cobain EF, Mehta RS, Gralow JR, Hortobagyi GN, Albain K, Pusztai L, Sharma P, Godwin AK, Thompson AM, Hayes DF, Rae JM. Thymidine Kinase Activity Levels in Serum Can Identify HR + Metastatic Breast Cancer Patients with a Low Risk of Early Progression (SWOG S0226). *Biomarkers* 28(3):313-322, 2023. PMID: 36647745
268. Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol* 24(2):162-174, 2023. PMID: 36623515
269. Rodriguez G, Mancuso J, Lyman GH, Cardoso F, Nahleh Z, Vose JM, Gralow JR, Francisco M, Sherwood S. ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology. *JCO Oncol Pract* Apr 7, 2023. Online ahead of print. PMID: 37027797
270. Kurbegov D, Bruinooge SS, Lei XJ, Kirkwood MK, Dickson N, Hattiangadi T, Mileham KF, Patrick A, Williams JH, Kaltenbaugh M, Gralow JR, Garrett-Mayer E. Rate of COVID-19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome-coronavirus 2: Analysis of the American Society of Clinical Oncology Registry. *Cancer* 6(5):e2311673, 2023. PMID: 36920457
271. Cannioto RA, Attwood KM, Davis EW, Mendicino LA, Hutson A, Zirpoli GR, Tang L, Nair NM, Barlow W, Hershman DL, Unger JM, Moore HCF, Isaacs C, Hobday TJ, Hortobagyi GN, Gralow JR, Albain KS, Budd GT, Ambrosone CB. Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. *JAMA Netw Open* 6(5):e2311673, 2023. PMID: 37140922

Abstracts:

1. Gralow J, Levy R, Miller RA. Spontaneous and Induced Immunoglobulin Secretion and Differentiation in Human B-Cell Lymphomas and Leukemias. *Federation Proceedings, Federation of American Societies for Experimental Biology*, 42:3, 1983.
2. Dubeau L, Chandler L, Gralow J, Nichols PW, Jones PA. Southern Blotting of DNA from Formalin-Fixed, Paraffin Embedded Tissue. *International Academy of Pathology*, 1986.

3. Dubeau L, Chandler L, Gralow J, Nichols PW, Jones PA. Recovery of Intact, High Molecular Weight DNA from Formalin-Fixed, Paraffin Embedded Pathology Specimens. American Urological Association, 1986.
4. Gralow JR, Dubeau L, Jones PA. Methylation Patterns of the Alpha-Lactalbumin Gene in Human Mammary Carcinoma: A Model for Identification of the Origin of Metastatic Tumors. Clinical Research, 1988.
5. Disis ML, Bernhard H, Gralow JR, Cheever MA. Existent T cell and Antibody Immunity to HER-2/neu Protein in Breast Cancer Patients. Proceedings of the American Association for Cancer Research 35:2966, 1994.
6. Disis ML, Gralow JR, Bernhard H, Hand S, and Cheever MA. Immunization to oncogenic HER-2/neu protein with peptide based vaccines. Proceedings of the American Association for Cancer Research 36: 1498, 1995.
7. Bernhard H, Disis ML, Huseby E, Hand S, Gralow JR, Risdon G, Heimfeld S, and Cheever MA. Generation of immunostimulatory dendritic cells from human CD34⁺ hematopoietic progenitor cells of the bone marrow and peripheral blood. Keystone Symposia, 1995.
8. Gralow JR, Weiner LM, Ring D, Clark J, Alpaugh RK, Disis ML, Cheever MA. HER-2/neu Specific Immunity Can Be Induced by Therapy with 2B1, a Bispecific Antibody Binding to HER-2/neu and CD16. IVth International Conference on Bispecific Antibodies and Targeted Cellular Toxicity, 1995.
9. Disis ML, Bernhard H, Shiota F, Hand S, Gralow JR, and Cheever MA. GM-CSF: An effective adjuvant for peptide based vaccines. The Ninth International Congress of Immunology.
10. Gralow JR, Weiner LM, Ring D, Clark J, Alpaugh RK, Disis ML, Cheever MA. HER-2/neu Specific Immunity Can Be Induced by Therapy with 2B1, a Bispecific Antibody Binding to HER-2/neu and CD16. American Society of Clinical Oncology, 1995.
11. Clark JI, Gralow JR, Alpaugh RK, Disis ML, Cheever MA, Ring D, and Weiner LM Bispecific Monoclonal Antibody-Promoted Induction of the Idiotype Cascade in a Phase I Clinical Trial. Proceedings of the American Association for Cancer Research 36: 2971, 1995.
12. Specht JS, Sivam GP, Gralow JR. Therapeutic Efficacy of Doxorubicin Immunoconjugates Targeting the HER-2/neu Oncogenic Protein in a Human Breast Cancer Cell Line. Journal of Investigative Medicine 44: 136A, 1996.
13. Hand SL, Bernhard H, Huseby ES, Gralow JR, Disis ML, Batten WY, Ohlen C, Cheever MA. Dendritic Cells Lose Ability to Present Protein Antigen after Stimulating Antigen-Specific T Cell Responses, Despite Upregulation of MHC Class II Expression. AAI, 1996.
14. Mankoff DA, Gralow JR, Dunnwald LK, Drucker MJ, Ellis G, Livingston RB. [Tc-99m]-Sestamibi Scintimammography to Measure the Breast Cancer Response to Neo-Adjuvant Chemotherapy. Journal of Nuclear Medicine 1130, 1996.
15. Mankoff DA, Gralow JR, Dunnwald LK, Drucker MJ, Ellis G, Livingston RB. Monitoring Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients Using [Tc-99m]-

- Sestamibi Scintimammography. Proceedings of the American Society of Clinical Oncology 15: 214, 1996.
16. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston R. Monitoring and Predicting the Response of Breast Cancer to Neo-adjuvant Chemotherapy Using [TC99m]-Sestamibi Scintimammography. Society of Nuclear Medicine 1997.
 17. Livingston RB, Gralow JR, Ellis GK, Williams MA. Taxol by 96-hour Infusion and Sequential Navelbine with GCSF Support as Salvage Therapy for Breast Cancer. A Phase I-II Study. Bristol Myers Squibb Investigator's Meeting, April 1997.
 18. Gralow JR, Mankoff DA. The Role of Imaging Modalities in the Diagnosis and Treatment of Breast Cancer. Society of Nuclear Medicine, Western Section. October 1996.
 19. Mankoff DA, Maravilla K, Austin-Seymour M, Ellis GK, Hayes C, Gralow JR, Cortese AA, Moe R. Combined PET and Surface Coil MRI Imaging in the Diagnosis of Recurrent Breast Cancer in the Axilla. San Antonio Breast Cancer Symposium. December 1996.
 20. Specht JS, Sivam GP, Gralow JR. Therapeutic Efficacy of Doxorubicin Immunoconjugates Targeting the HER-2/neu Oncogenic Protein in Human Breast Cancer. Proceedings of the American Society of Clinical Oncology 16: 1997.
 21. Zapf ML, Folpe AL, Storer BE, Gown AM, Ellis GK, Livingston RB, Gralow JR. Cellular Tumor Markers as Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer. Breast Ca Res and Treat 46: 66, 1997.
 22. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston R. Monitoring Locally Advanced Breast Cancer Treatment Response using [Tc-99m]-Sestamibi scintimammography. Breast Ca Res and Treat 46:74, 1997.
 23. Ellis GK, Williams M, Gralow J, Long C, Livingston RB. Continuous Adriamycin and Cyclophosphamide with GCSF Feasible with High Dose Intensity, Low Risk of Hospitalization. Breast Ca Res and Treat 46:74, 1997.
 24. Gralow JR, Zapf ML, Folpe AL, Ellis GK, Livingston RB, Gown AM. Alterations in Breast Cancer Protein Expression Following Neoadjuvant Doxorubicin-based Chemotherapy. Breast Ca Res and Treat 46: 75, 1997.
 25. Lindgren C, Markowitz D, Gralow J, Keeler T, Bennett S, Golden J, Bensinger W, Holmberg L, Thompson JA, Fefer A. IL-12 Induces Cytolytic Activity in Lymphocytes from Breast Cancer Patients after High Dose Therapies. Proceedings of the American Society of Clinical Oncology 17: 1998.
 26. Zapf ML, Folpe AL, Storer BE, Gown AM, Ellis GK, Livingston RB, Gralow JR. Breast Cancer Tumor Associated Proteins as Predictors of Response to Neoadjuvant Doxorubicin-Based Chemotherapy. Proceedings of the American Society of Clinical Oncology 17: 1998.
 27. Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingston RB. Paclitaxel/Vinorelbine Chemotherapy with Concurrent G-CSF for Metastatic Breast Cancer: Phase I-II Study in Doxorubicin-Treated Patients. Proceedings of the American Society of Clinical Oncology 17: 1998.

28. Gralow JR, Zapf ML, Folpe AL, Ellis GK, Livingston RL, Gown AM. Neoadjuvant Chemotherapy Induces Alterations in Breast Cancer Protein Expression. *Proceedings of the American Society of Clinical Oncology* 17: 1998.
29. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Olsen T, Livingston RB. Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy. *Society of Nuclear Medicine* 1998.
30. Mankoff DA, Tewson TJ, Yaziji H, Gralow JR, Lehr HA, Gown AM. [F-18]-Fluoroestradiol Imaging of Estrogen Receptors: Correlation with Immunocytochemistry. *Society of Nuclear Medicine* 1998.
31. Eubank WB, Mankoff DA, Shanley TJ, Gralow JR, Ellis GK, Lindsley KL, Austin-Seymour MM, Livingston RB, Charlop A. [F18]-Fluorodeoxyglucose and Positron Emission Tomography to Detect Mediastinal or Internal Mammary Node Metastases in Advanced Breast Cancer. *Proceedings of the American Society of Clinical Oncology* 18: 1999.
32. Gralow JR, Ellis GK, Williams MA, Livingston RB. Docetaxel + Vinorelbine with concurrent G-CSF Support: A Phase II Study in Stage IV Breast Cancer. *Breast Ca Res Treat* 1999.
33. Gralow JR, Martsynskovskaya NV, Maystruk G, Bowls DL, Dammann K, Doan RN. Ukraine Breast Cancer Assistance Project: A Trial of Neoadjuvant Doxorubicin and Cyclophosphamide. *Breast Ca Res Treat* 1999.
34. Gralow JR, Ellis GK, Williams MA, Livingston RB. Docetaxel and vinorelbine with concurrent G-CSF support: A phase II study in stage IV breast cancer. *Proceedings of the American Society of Clinical Oncology* 19: 2000.
35. Livingston RB, Williams MA, Ellis GK, Gralow JR, Long C. Dose-dense, dose-intensive doxorubicin and cyclophosphamide with concurrent G-CSF: Results of adjuvant therapy in patients with 4-9 positive nodes. *Proceedings of the American Society of Clinical Oncology* 19: 2000.
36. Rinn KJ, Livingston RB, Gralow JR, Thompson T, Vernon C, Williams M, Ellis GK. Adjuvant cyclophosphamide, etoposide and cisplatin (CEP) without stem cell rescue as consolidation for high risk localized breast cancer. *Proceedings of the American Society of Clinical Oncology* 19: 2000.
37. Ellis GK, Thompson T, Craig V, rinn K, Gralow J, Livingston RB. Feasibility of full dose docetaxel after dose-intensive doxorubicin as adjuvant therapy for high-risk primary breast cancer. *Breast Ca Res Treat* 2000.
38. Leith PO, Rendleman AA, Davis HL, McCune JS, Winter L, Ellis GK, Gralow JR, Livingston RB. Weoght-based weekly dosing of Epoetin Alpha is effective for chemotherapy-induced anemia in cancer patients. *Proceedings of the American Society of Clinical Oncology* 20:2001.
39. Livingston RB, Ellis GK, Gralow JR, Thompson T. Dose dense adjuvant therapy in node positive breast cancer: weekly doxorubicin, daily oral cyclophosphamide and filgrastin +/- 5FU. Results at 5 years. *Proceedings of the American Society of Clinical Oncology* 20:2001.

40. Yaziji H, Gralow JR, Chahal M, Zapf M, Thomazy V, Davies P, Davie P, Gown AM. HER-2/neu detection by fluorescence in situ hybridization and reverse transcriptase chain reaction in breast cancers with low level overexpression by immunohistochemistry. *Proceedings of the American Society of Clinical Oncology* 20:2001.
41. Mankoff DM, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Schubert EK, Livingston RB. [99m]Tc-sestamibi uptake and washout in locally advanced breast cancer correlates with tumor blood flow. *Society of Nuclear Medicine* 2001.
42. Stafford SE, Gralow JR, Schubert EK, Dunnwald LK, Livingston RB, Mankoff DA. Serial FDG PET measures response to therapy in bone-dominant breast cancer. *Society of Nuclear Medicine* 2001.
43. Goodwin JW, Green SJ, Giarritta S, Giguere JK, Hoelzer K, Bearden J, Livingston RB, Gralow JR, Ganz PA, Martino S, Albain KS. Double blind phase III trial of placebo vs. megestrol acetate 20 mg vs. megestrol acetate 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group 9626. *Breast Ca Res Treat* 2001.
44. Stafford SE, Gralow JR, Schubert EK, Dunnwald LK, Livingston RB, Rinn KJ, Mankoff DA. A new measure of response to therapy in bone-dominant breast cancer: a pilot study of serial quantitative F-(18)-Fluorodeoxyglucose Positron Emission Tomography. *Breast Ca Res Treat* 2001.
45. Ellis GK, Livingston RB, Gralow JR, Thompson T. Dose-intense, dose-dense, (F)AC+G adjuvant chemotherapy has excellent event-free survival in high-risk patients with 4-9 involved axillary nodes. *Breast Ca Res Treat* 2001.
46. Hudis CA, Williams D, Gralow JR, The Procrit Study Group. Role of epoetin alpha in maintaining hemoglobin and quality of life in breast cancer patients receiving adjuvant chemotherapy or chemoradiation. *Breast Ca Res Treat* 2001.
47. Schwartz AL, Cunningham K, King ME, Fow L, Gralow JR. A randomized trial to examine effects of exercise on bone density and body composition in breast cancer patients receiving adjuvant chemotherapy. *Breast Ca Res Treat* 2001.
48. Hudis C, Williams D, Gralow JR. Epoetin alfa maintains hemoglobin levels and quality of life in breast cancer patients during conventional adjuvant chemotherapy. *Proceedings of the American Society of Clinical Oncology* 21:2002.
49. Yaziji H, Gralow JR, Gown AM. Cost-effective tissue-based HER-2/neu testing in breast cancer: emphasis on patient demographics and tumor histology. *Proceedings of the American Society of Clinical Oncology* 21:2002.
50. Mankoff DA, Dunnwald LK, Schubert EK, Tseng J, Gralow JR, Ellis GK, Linden HM, Livingston RB. Post-therapy imaging parameters predict survival in locally-advanced breast cancer: quantitative radiotracer imaging as a surrogate endpoint for clinical trials. *Society of Nuclear Medicine* 2002.
51. Tseng J, Dunnwald LK, Schubert EK, Minoshima S, Gralow JR, Ellis GK, Linden HM, Livingston RB, Lawton TJ, Mankoff DA. Metabolism and blood flow in treated locally advanced breast cancer. *Society of Nuclear Medicine* 2002.

52. Tseng J, Dunnwald LK, Schubert EK, Gralow JR, Ellis GK, Linden HM, Livingston RB, Lawton TJ, Mankoff DA. Blood flow changes are predictive of pathologic tumor response and lymph node status after neo-adjuvant chemotherapy in locally advanced breast cancer. Society of Nuclear Medicine 2002.
53. Mankoff DA, Peterson LM, Stekhova S, Schubert EK, Link JM, Gralow JR, Linden HM, Livingston RB, Krohn KA. Recurrent breast cancer uptake of [F-18]-fluoroestradiol (FES) predicts response of recurrent or metastatic breast cancer to hormonal therapy. Society of Nuclear Medicine 2002.
54. Hudis, Williams D, Gralow J. Final report: Epoetin alfa maintains hemoglobin levels and quality of life in breast cancer patients during conventional adjuvant chemotherapy. Breast Ca Res Treat 2002.
55. Ganz PA, Green SJ, Hutchins L, Martino S, Gralow J, Livingston R, Albain KS. Late cardiac effects of adjuvant CMF vs CAF in women with node-negative breast cancer treated on SWOG 8897: initial results from SWOG 9342. Breast Ca Res Treat 2002.
56. Palomares MR, Richardson-Lander A, Koehler KM, Gralow JR, Sabath DE. Qualitative real-time RT-PCR for the detection of circulating breast cancer cells: correlation with stage and treatment. Breast Ca Res Treat 2002.
57. Pierce LJ, Hutchins L, Green SJ, Lew D, Gralow J, Livingston RB, Osborne CK, Albain KS. Sequencing of tamoxifen and radiotherapy with breast conservation in early stage breast cancer. Proceedings of the American Society of Clinical Oncology 22:2003.
58. Ellis GK, Livingston RB, Rinn K, Gralow J, Thompson T. Pilot adjuvant study: 12 weeks of dose dense doxorubicin with scheduled G-CSF support followed by 4 cycles of docetaxel. Proceedings of the American Society of Clinical Oncology 22:2003.
59. Mankoff DA, Dunnwald LK, Schubert EK, Gralow JR, Ellis GK, Linden HM, Livingston RB. Residual tumor uptake of [Tc-99m]-sestamibi after neoadjuvant chemotherapy for locally advanced breast cancer predicts survival. Proceedings of the American Society of Clinical Oncology 22:2003.
60. Hudis, Williams D, Gralow J. Epoetin alfa maintains hemoglobin levels and quality of life in breast cancer patients during conventional adjuvant chemotherapy: Final report. Proceedings of the American Society of Clinical Oncology 22:2003.
61. Thomas E, Bunnell CA, Vahdat LT, Schwartzberg LS, Gralow JR, Whitaker LM, Peck R. A phase I study of BMS-247550 in combination with capecitabine in patients with metastatic breast cancer previously treated with a taxane and an anthracycline. Breast Ca Res Treat 22:2003.
62. Palomares M, Goldstein L, Lehman CD, Hopper L, Gralow JR. Feasibility of breast tissue sampling in a chemoprevention trial with histologic biomarker endpoints. Breast Ca Res Treat 22: 2003.
63. Coleman R, Gralow J, Bell R, Lipton A. Zoledronic acid for the prevention of bone metastases in patients with breast cancer. Eur Breast Cancer Conf 2004.
64. Theriault R, Jakesz R, Gnant M, Gralow J. The evolving role of bisphosphonates for the prevention of cancer treatment-induced bone loss in patients with breast cancer. Eur Breast Cancer Conf 2004.

65. Palomares MR, Hopper L, Goldstein L, Lehman CD, Gralow JR. Acceptability of breast core biopsy as a tissue sampling method for a chemoprevention trial. *Proceedings of the American Association for Cancer Research* 2004.
66. Tam S, Gumerlock P, Galvin I, Kimura T, Livingston R, Thompson T, Gralow J. Beta-tubulin III isotype expression and response to anti-tubulin therapy in metastatic breast cancer. *Proc Am Soc Clin Oncol* 23:2004.
67. Palomares MR, Hopper L, Goldstein L, Lampe JW, Storer BE, Gralow JR. Effect of soy isoflavones on breast proliferation in postmenopausal breast cancer survivors. *Breast Ca Res Treat* 88: 2004.
68. Johnson G, Gralow J, Benson P. Use of bisphosphonates for the palliative care of metastatic bone pain. *Eur Soc Med Oncol* 2004.
69. Ellis GK, Thompson T, Linden HM, Rinn K, Murphy AE, Gralow JR, Livingston RB. Adjuvant weekly "AC + G" followed by weekly paclitaxel shows good efficacy in node-positive breast cancer at two years median follow-up. *Proc Am Soc Clin Oncol* 24:2005.
70. Tam SL, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA. Serial FDG-PET to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression. *Proc Am Soc Clin Oncol* 24:2005.
71. Gralow J, Green S, Lew D, Barlow W, Dammann K, Somlo G, Rivkin S, Taylor S, Wong L, Livingston R. SWOG 0102: A Phase II study of docetaxel and vinorelbine + filgrastim for HER-2 negative, stage IV breast cancer. *Proc Am Soc Clin Oncol* 24:2005.
72. Bearman SI, Green S, Gralow J, Barlow W, Hudis C, Wolff A, Ingle J, Hortobagyi G, Livingston R, Martino S. SWOG/Intergroup 9623: A phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic stem cell support for primary breast cancer in women with > 4 involved axillary lymph nodes. *Proc Am Soc Clin Oncol* 24:2005.
73. Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier TN, Davidson NE. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100). *ECCO* 2005, abstract #275.
74. Palomares MR, Schuster GT, Thomas A, Koehler KM, Gralow JR, Sabath DE. Monitoring circulating tumor cells by quantitative real time RT-PCR. *Breast Ca Res Treat* 94: 2005.
75. Gown AM, Treaba DO, Goldstein LC, Porter PL, Gralow JR, Livingston RB, Tam S, Yeh I-T, Hayes DF, Barlow W, Lew D. High expression of the microtubule-associated protein tau strongly predicts improved progression-free survival in patients with metastatic HER-2 negative breast cancers treated with docetaxel and vinorelbine plus filgrastim. *Breast Ca Res Treat* 94: 2005.
76. Linden HM, Link JM, Stekhova S, Livingston RB, Gralow JR, Ellis GK, Schubert EK, Peterson LM, Krohn A, Mankoff DA. Changes in estrogen binding to ER during endocrine therapy measured by serial [F-18]-fluoroestradiol positron emission tomography. *Breast Ca Res Treat* 94: 2005.
77. Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier TN, Davidson NE. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab for locally recurrent or

metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). *Breast Ca Res Treat* 94: 2005.

78. Gralow JR, Brenner W, Linden HM, Livingston RB, Ellis GK, Schubert EK, Peterson LM, Muzi M, Mankoff DA. Changes in tumor metabolism and local bone turnover in patients treated for bone-dominant metastatic breast cancer measured by fluorodeoxyglucose and fluoride positron emission tomography. *Breast Ca Res Treat* 94: 2005.
79. Gralow J, Paterson A. S0307: A phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. Eighth Workshop on Bisphosphonates, Davos, Switzerland 2006.
80. Gralow JR, Chielens D, Schuster G, Storer B, McCleod MJ, Smith RE, Chowhan N, Gressler V, Miletello G. UW-01: A randomized comparison of three doses of weekly docetaxel as 1st-line chemotherapy in stage IV breast cancer. *Proc Am Soc Clin Oncol* 24:2006.
81. Gown AM, Goldstein LC, Porter PL, Livingston RB, Tam S, Yeh I, Barlow WE, Gralow JR, Hayes DF. Multivariate analysis of expression of the microtubule-associated protein, tau, predicts improved progression free and overall survival in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim. *Proc Am Soc Clin Oncol* 24:2006.
82. Linden HM, Stekhova S, Link JM, Livingston RB, Gralow JR, Ellis GK, Peterson LM, Schubert ES, Krohn KA, Mankoff DA. Understanding resistance to hormonal therapy in estrogen avid breast cancer. *Proc Am Soc Clin Oncol* 24:2006.
83. Chew HK, Barlow W, Albain K, Lew D, Budd T, Allen G, Gralow J, Livingston R. SWOG 0338: A phase II trial of imatinib mesylate in combination with capecitabine in metastatic breast cancer. *Proc Am Soc Clin Oncol* 24:2006.
84. Wagner L, Wang M, Miller K, Davidson NE, Gralow J, Dickler M, Cobleigh M, Perez E, Shenkler T, Cella D. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: Results from the eastern cooperative oncology group study 2100. *Breast Ca Res Treat* 100: 2006.
85. Dunnwald L, Gralow J, Ellis G, Livingston R, Linden H, Specht J, Doot R, Lawton T, Barlow W, Mankoff D. Tumor metabolism, blood flow changes, and prognosis by positron emission tomography: A prospective cohort of locally advanced breast cancer patients. *Proc Am Soc Clin Oncol* 25:2007.
86. Mankoff DA, Dunnwald L, Gralow J, Ellis G, Linden H, Specht J, Doot R, Barlow W, Schubert E, Livingston R. Use of changes in blood flow PET measurements to predict post-therapy lymph node status among locally advanced breast cancer patients. *Proc Am Soc Clin Oncol* 25:2007.
87. Linden HM, Mankoff DA, Krohn KA, Link JM, Stekhova S, Livingston RB, Gralow JR, Ellis GK, Kurland B, Peterson L, Schubert EK. PET FES measures in vivo pharmacodynamics of endocrine therapy. *Proc Am Soc Clin Oncol* 25:2007.
88. Nordstrom BL, Langer C, Hussain A, Barghout V, Modi D, Lacerna L, Gralow JR. Renal function among cancer patients with bone metastases treated with zoledronic acid in a real world setting. *Proc Am Soc Clin Oncol* 25:2007.

89. Gralow J, Lipton A, Fizazi K, Fan M, Wu L, Jun S. Denosumab treatment of cancer patients with bone metastases and elevated urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a phase II randomized trial. Proc Am Soc Clin Oncol, Breast Cancer Symposium 2007.
90. Gralow JR, Barlow WE, Gown AM, Goldstein LC, Porter PL, Yeh I-T, Livingston RB, Hayes DF. Expression of the microtubule-associated protein, tau, predicts improved survival, but not response, to a combination of docetaxel and vinorelbine in HER-2 negative metastatic breast cancer. Breast Cancer Treat: 2007.
91. Gralow JR, Lipton A, Fizazi K, Body J, Steger GG, Gao G, Yeh H. Effects of denosumab on bone resorption in patients with solid tumors and bone metastases: Comparison of serum-C telopeptide levels from two randomized, active-controlled, phase II trials. J Clin Oncol 26: 2008 (abstract 9574).
92. Partridge AH, Archer LE, Kornblith AB, Gralow JR, Grenier D, Perez EA, Wolff AC, Hudis CA, Winer EP, Muss H. CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907. J Clin Oncol 26: 2008 (abstract 6542).
93. Fizazi K, Lipton A, Mariette X, Suarez T, Body J, Rahim Y, Gralow JR, Gao G, Wu L, Jun S. Denosumab in patients with bone metastases from prostate, breast, and other cancers and elevated urinary N-telopeptide (uNTx) during intravenous bisphosphonate (IV BP) therapy: Final results of a randomized, phase II study. J Clin Oncol 26: 2008 (abstract 3596).
94. Klencke BJ, Bhattacharya S, Samant MK, Gralow JR, Dickler MN, MA, Perez EA, Shenkier TN, Davidson NE, Miller KD. Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC). J Clin Oncol 26: 2008 (abstract 1036).
95. Nelson M, Blum DS, Gralow JR, Cardoso F, Grande C, Palmieri FM, Kirk MC, Eagan C. Oncologist and patient roles in assessing current and future treatment for metastatic breast cancer: Results of an observational linguistic study. J Clin Oncol 26: 2008 (abstract 1064).
96. Kash J, Barlow WE, Albain KS, Gralow JR, Lew D, Flaherty LE, Royce ME, Hortobagyi GN, Livingston RB. Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. J Clin Oncol 26: 2008 (abstract 1033).
97. Lipton A, Fizazi K, Gralow J, Body J, Gao G, Jun S. Denosumab treatment in patients with bone metastases and excessive bone resorption despite intravenous bisphosphonate (IV BP) therapy. Breast Cancer Symposium 2008 (abstract 174).
98. Specht JM, Kurland BF, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston RB, Schubert EK, Mankoff DA. Metabolism-perfusion mismatch as assessed by PET varies with breast cancer phenotype and predicts response to neoadjuvant chemotherapy. San Antonio Breast Cancer Symposium 2008 (abstract 6005).
99. Specht JM, Partridge S, Dunnwald L, Doot R, Schubert E, Kurland B, Gralow J, Linden H, Gadi VK, Ellis G, Mankoff D. DCE-MRI and dynamic FDG PET to monitor breast cancer response to neoadjuvant sunitinib in patients with locally-advanced breast cancer. San Antonio Breast Cancer Symposium 2008 (abstract 6006).

100. Gralow J, Lipton A, Fizazi K, Gao G, Jun S, Yeh H. Effects of denosumab treatment in breast cancer patients with bone metastases and elevated bone resorption levels after therapy with intravenous bisphosphonates: results of a phase 2 randomized trial. San Antonio Breast Cancer Symposium 2008 (abstract 1155).
101. Palomares MR, Rodriguez J, Banzet M, Thomas A, Schuster GT, Koehler KM, Gralow JR, Sabath DE. Serial measurements of circulating tumor cells by quantitative RT-PCR in metastatic breast cancer patients receiving systemic therapy. San Antonio Breast Cancer Symposium 2008 (abstract 5027).
102. Linden HM, Kurland BF, Livingston RB, Ellis GK, V. K. Gadi VK, Specht JM, Gralow JR, Mankoff DA, Peterson LM, Schubert EK. Early assessment of response to aromatase inhibitor (AI) therapy. J Clin Oncol 27, 2009 (abstract 11075).
103. Perez EA, Suman VJ, Davidson NE, Gralow J, Kaufman PA, Ingle JN, Dakhil SR, Zujewski JA, Pisansky TM, Jenkins RB. Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial. San Antonio Breast Cancer Symposium 2009 (abstract 80).
104. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh I-T, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). San Antonio Breast Cancer Symposium 2009 (abstract 112).
105. Perez EA, Reinholz MM, Dueck AC, Tenner KS, Davidson NE, Gralow J, Harris L, Kutteh L, Jenkins RB, Chen B. Do the ASCO/CAP 2007 HER2 Testing Guidelines Improve Prediction of Benefit to Adjuvant Trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant Trial. San Antonio Breast Cancer Symposium 2009 (abstract 701).
106. Ambrosone CB, Sucheston LE, Zhao H, Yao S, Budd GT, Barlow WE, Hershman DL, Davis W, Ciupak G, Stewart JA, Isaacs C, Hobday T, Latreille J, Hortobagyi GN, Gralow JR, Livingston R, Albain KS, Hayes DF. Variants in the BRCA1/Fanconi-Anemia Repair Pathway and Taxane-Induced Neuropathy in SWOG S0221. San Antonio Breast Cancer Symposium 2009 (abstract 2001).
107. Javid SH, Unger JM, Gralow JR, Moinpour CM, Wozniak AJ, Goodwin JW, Lara PN, Williams PA, Hutchins LF, Gotay CC, Albain KS. The Influence of Older Age on Physician and Patient Decision-Making Regarding Enrollment to Breast Cancer Clinical Trials. San Antonio Breast Cancer Symposium 2009 (abstract 3077).
108. Reinholz MM, Dueck AC, Wiktor AE, Lingle WL, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Geiger X, Perez EA. c-MYC (MYC) Protein Expression and Associations with Trastuzumab Benefit in Early-Stage, HER2+ Breast Cancer in Context of the NCCTG Adjuvant Trial, N9831. San Antonio Breast Cancer Symposium 2010, Abstract P2-09-08
109. Reinholz MM, Dueck AC, Chen B, Geiger X, McCullough AE, Jenkins RB, Lingle WL, Andorfer C, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris L, Gralow J, Perez EA.

Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. J Clin Oncol 29: 2011 (suppl; abstr 10503)

110. Gonzalez-Angulo AM, Barlow WE, Gralow J, Meric-Bernstam F, Hayes DF, Moinpour C, Ramsey SD, Schott AF, Sparks DB, Albain KS, Hortobagyi GN. SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. J Clin Oncol 29: 2011 (suppl; abstr TPS104)
111. Perez EA, Dueck AC, Reinholz MM, Chen B, Geiger X, Jenkins RB, Lingle WL, Andorfer C, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris L, Gralow J, McCullough AE. Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. J Clin Oncol 29: 2011 (suppl; abstr 10504)
112. Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, C. Isaacs C, M. Salim M, J. K. Cho JK, K. Rinn K, K. S. Albain KS, H. K. Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BAFlaherty LE, Livingston RB, Lew D, Gralow J, Hortobagyi GN. First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 1004)
113. Linden HM, Kurland BF, Livingston RB, Ellis GK, Gadi VK, Specht JM, Gralow J, Peterson L, Schubert EK, Xiaoyu S, Mankoff DA. Changes in FDG PET SUV and correlation with Ki-67 following 2 weeks of aromatase inhibitor therapy or trastuzumab in a pilot imaging study. J Clin Oncol 29: 2011 (suppl; abstr e21077)
114. Vogel CL, Bloom K, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Brammer MG, Kaufman PA. Discordance between Central and Local Laboratory HER2 Testing from a Large HER2-Negative Population in VIRGO, a Metastatic Breast Cancer Registry. San Antonio Breast Cancer Symposium 2011, Abstract P1-07-02
115. Mehta RS, Barlow WE, Albain KS, Vandenberg T, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226. San Antonio Breast Cancer Symposium 2011, Abstract S1-1
116. Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE, Swain SM, Costantino JP, Mamounas EP, Wolmark N. NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. San Antonio Breast Cancer Symposium, Abstract S2-3
117. Perez EA, Ballman KV, Reinholz MM, Dueck AC, Cheng H, Jenkins RB, McCullough AE, Chen B, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Geiger XJ, Ingle JN, Tenner KS, Harris LN, Gralow JR, Rimm DL. Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831. San Antonio Breast Cancer Symposium 2011, Abstract PD05-03

118. Blum JL, Barrios CH, Feldman N, Verma S, McKenna E, Lee S, Scotto N, Gralow J. Pooled Analysis of Individual Patient Data from Capecitabine Monotherapy Clinical Trials in Anthracycline-/Taxane-Pretreated Locally Advanced or Metastatic Breast Cancer (LA/MBC). San Antonio Breast Cancer Symposium 2011, Abstract P5-19-08
119. Gonzalez-Angulo AM, Barlow WE, Gralow JR, Meric-Bernstam F, Hayes DF, Moinpour CM, Ramsey SD, Schott AF, Sparks DB, Albain KS, Hortobagyi GN. A Randomized Phase III Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients (pts) with 1-3 Positive Nodes, Hormone Receptor (HR)-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less: SWOG S1007. San Antonio Breast Cancer Symposium 2011, Abstract OT1-03-01
120. Rodler ET, Specht JM, Gadi VK, Kurland BF, Griffin MJ, Hammond JJ, Gralow JR. Phase I Study of PARP Inhibitor ABT-888 (Veliparib) in Combination with Cisplatin and Vinorelbine for Patients with Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer. San Antonio Breast Cancer Symposium 2011, Abstract P1-17-04
121. Linden HM, Kurland BF, Jeanne Link J, Gadi VK, Specht JM, Gralow J, Schubert EK, Peterson L, Eary JF, Mankoff DM. Vorinostat to restore sensitivity to aromatase inhibitor therapy in meta static breast cancer: A phase II clinical trial with ER imaging correlates. J Clin Oncol 30, 2012 (suppl; abstr TPS3109)
122. Thariani R, Blough DK, Barlow W, Henry NL, Gralow J, Ramsey SD, Veenstra DL. Evaluating the impact of a trial in breast cancer tumor markers: A value of research analysis. J Clin Oncol 30, 2012 (suppl; abstr e16524)
123. Shao T, Shane ES, McMahon D, Crew KD, Kalinsky K, Maurer M, Brown M, Gralow JR, Hershman DL. Effects of High Dose of Bisphosphonate Therapy on Bone Microarchitecture of the Peripheral Skeleton in Women with Early Stage Breast Cancer. San Antonio Breast Cancer Symposium 2012, Abstract P6-12-03
124. Linden HM, Kurland BF, Specht JM, Vijayakrishn GK, Gralow JR, Peterson LM, Schubert EK, Link JM, David MA, Eary JF, Krohn KA. Changes in Breast Tumor Metabolism and Estradiol Binding as Measured by FES PET in Patients Treated with the Histone Deacetylase Inhibitor Vorinostat and Aromatase Inhibitor Therapy. San Antonio Breast Cancer Symposium 2012, Abstract P6-04-03
125. Perez EA, Eckel-Passow JE, Ballman KV, Anderson SK, Thompson EA, Asmann YW, Jen J, Dueck AC, Lingle WL, Sledge GW, Winer EP, Gralow J, Jenkins RB, Reinholz MM. Predictive Genomic Markers To Chemotherapy and Adjuvant Trastuzumab Via Whole Genome Expression DASL Profiling in the N9831 Adjuvant Study. San Antonio Breast Cancer Symposium 2012, Abstract PD10-04
126. Romond E, Suman VJ, Jeong J-H, Sledge, Jr. GW, Geyer, Jr. CE, Martino S, Rastogi P, Gralow J, Swain SM, Winer E, Colon-Otero G, Hudis C, Paik S, Davidson N, Mamounas EP, Zujewski JA, Wolmark N, Perez EA. Trastuzumab Plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival (OS) from NSABP B-31 and NCCTG N9831. San Antonio Breast Cancer Symposium 2012, Abstract S5-5

127. Rimm D, Ballman KV, Cheng H, Vassilakopoulou M, Chen B, Gralow J, Hudis C, Davidson NE, Psyrri A, Fountzilas G, Perez EA. EGFR Expression Measured by Quantitative Immunofluorescence Is Associated with Decreased Benefit from Trastuzumab in the Adjuvant Setting in the NCCTG (Alliance) N9831 Trial. San Antonio Breast Cancer Symposium 2012, Abstract S5-4
128. Perez EA, Butler SM, Dueck AC, Baehner FL, Jamshidian F, Cherbavaz DB, Thompson EA, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann YW, Ballman KV. The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831. J Clin Oncol 31, 2013 (suppl; abstr 520)
129. Specht JM, Kurland BF, Linden HM, Gralow J, Gadi VK, Ellis GK, Rodler ET, Chai X, Eun J, Brown-Glaberman UA, Livingston RB. A phase II study evaluating the safety and efficacy of sunitinib with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy (NC) for locally advanced (LABC) or inflammatory breast cancer (IBC). J Clin Oncol 31, 2013 (suppl; abstr 1090)
130. Lichtman SM, CCirrincione C, Hurria A, Jatoi A, Theodoulou M, Wolff AC, Gralow J, Morganstern D, Magrinat G, Cohen HJ, Muss H. Effect of renal function (RF) on outcomes in the adjuvant treatment of older women with breast cancer (>65 years): CALGB/CTSU 49907 (CC) ancillary data study. J Clin Oncol 31, 2013 (suppl; abstr 9515)
131. Budd GT, Barlow E, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn K, Albain KS, Chew HK, Von Burton G, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew D, Gralow J, Hortobagyi GN. S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. J Clin Oncol 31, 2013 (suppl; abstr CRA1008)
132. Gralow J. Promoting Cancer Advocacy Globally: The Women's Empowerment Cancer Advocacy Network (WE CAN) Experience. ASCO 2013 Education Session.
133. Coleman R, Gnant M, Paterson A, Powles T, von Minckwitz G, Pritchard K, Bergh J, Bliss J, Gralow J, Anderson S, Evans V, Pan H, Bradley R, Davies C, Gray R, On Behalf of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG)'s Bisphosphonate Working Group. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. San Antonio Breast Cancer Symposium 2013, Abstract S4-07
134. Linden HM, Kurland BF, Link JM, Novakova A, Chai X, Specht JM, Gadi VK, Gralow JR, Schubert EK, Peterson LM, Eary J, Shields A, Mankoff DA, Krohn KA. HDACi (vorinostat) in metastatic breast cancer to restore sensitivity to ER-directed (AI) therapy: A phase II clinical trial with FES imaging correlates. San Antonio Breast Cancer Symposium 2013, Abstract P4-01-03
135. Linden HM, Kurland BF, Link JM, Novakova A, Chai X, Gadi VK, Specht JM, Hills D, Gralow JR, Schubert EK, Korde L, Peterson LM, Doot R, Eary J, Shields A, Krohn KA, Mankoff DA. The role of FLT PET early assessment of response to endocrine therapy for early stage breast cancer. San Antonio Breast Cancer Symposium 2013, Abstract P4-01-02
136. Montgomery SK, Barlow WE, Linden HM, Gralow JR, Ellis GK, Gadi VK, Schubert EK, Peterson LM, Novakova A, Doot R, Dunnwald LK, Mankoff DA, Specht JM. Serial FDG and 18F-fluoride PET predict response to therapy in patients with breast cancer bone metastases. San Antonio Breast Cancer Symposium 2013, Abstract P4-01-01

137. Smerage JB, Barlow WE, Hayes DF, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Gralow JR, Livingston RB, Hortobagyi GN. SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment. San Antonio Breast Cancer Symposium 2013, Abstract S5-07
138. Linden HM, Kurland BF, Link J, Novakova A, Chai X, Specht JM, Gadi VK, Gralow J, Schubert EK, Peterson L, Eary JF, Shields A, Mankoff DA, Krohn KA. A phase II clinical trial of HDACi (vorinostat) and AI therapy in breast cancer with molecular imaging correlates. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 556)
139. Gralow J, WE, Paterson AHG, Lew D, Stopeck A, Hayes DF, Hershman DL, Schubert M, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Livingston RB, Hortobagyi GN. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 558)
140. Perez EA, Thompson EA, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow J, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger X, McCullough AE, Chen B, Zschunke M, Jenkins RB, Sledge GW, Winer EP, Gralow J, Reinholz MM, Ballman KV. Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 509)
141. Dueck AC, Hillman DW, Kottschade LA, Halyard MY, Sloan JA, Flickinger LM, Wolff AC, Harris L, Gralow J, Pritchard KI, Ellard S, Le-Lindqwister N, Boyle FM, De Azambuja E, McCaskill-Stevens WJ, Zujewski JA, Piccart-Gebhart MJ, Perez EA. Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). *J Clin Oncol* 32:5s, 2014 (suppl; abstr 647)
142. Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Albain KS, Rinn K, Chew HK, Von Burton G, Moore TD, Gordan Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew D, Gralow J, Hortobagyi GN. Outcome of male patients and black patients enrolled in S0221, an intergroup chemotherapy study. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 1016)
143. Rodler ET, Gralow J, Kurland BF, Griffin M, Yeh R, Thompson JA, Porter P, Swisher EM, Gadi VK, Korde LA, Linden HM, Ellis GK, Shepherd SP, Giranda VL, Chai X, Hammond J, Hibbert R, Askovich B, Specht JM. Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 2569)
144. Hershman DL, Unger JM, Crew KD, Dakhil SR, Awad D, Greenlee H, Minasian LM, Hansen L, Lew D, Gralow J, Wade JL, Meyskens FL, Moinpour C. Omega-3 fatty acids for aromatase inhibitor-induced musculoskeletal symptoms in women with early-stage breast cancer (SWOG S0927). *J Clin Oncol* 32:5s, 2014 (suppl; abstr 9532)
145. Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Perez EA, Sikov WM, Chennuru S, Mirshahidi H, Vidito S, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women

with inflammatory or locally advanced breast cancer. San Antonio Breast Cancer Symposium 2014, abstract P3-11-16

146. Somlo G, Barlow W, Moore H, Gralow J, Schott A, Hayes D, Kuhn P, Hicks J, Lew D, Tripathy D, Hortobagyl G. Fulvestrant alone versus fulvestrant and everolimus versus fulvestrant, everolimus and anastrozole: A Phase III randomized, placebo-controlled trial in postmenopausal patients with hormone-receptor-positive stage IV breast cancer: SWOG-Clinical Trials Initiative S1222. San Antonio Breast Cancer Symposium 2014, abstract OT2-1-01
147. Blau CA, Pritchard C, Dorschner MO, Blau S, Mecham B, Mahen E, Gadi VK, Monsky W, Burton K, Ramirez A, Stilwell J, Kladjian E, Collins C, McCune JS, Noble WS, Gralow J, Senecal F, Dhaene L, Kuderer N, Specht J, Song C, Grandori C, Price N, Goldman M, Radenbaugh A, Haussler D, Zhu J. Assessing the safety and feasibility of efficient hypothesis testing in patients with metastatic triple negative breast cancer. San Antonio Breast Cancer Symposium 2014, abstract P4-08-01
148. Liu MC, Rack B, Dueck AC, Hillman DW, Campion MB, Reinholz MM, Halling KC, Sotiriou C, Rothé F, Maetens M, Rouas G, Janni W, Wolff AC, Harris LN, Gralow JR, Pritchard KI, Ellard S, Le-Lindqwister NA, Boyle F, De Azambuja E, Piccart-Gebhart MJ, Ignatiadis M, Perez EA. Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial. San Antonio Breast Cancer Symposium 2014, abstract P4-01-01
149. Chavez-Mac Gregor M, Barlow WE, Lajos Pusztai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Gralow J, Danika L, Lew DL, Hortobagyi GN. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140). J Clin Oncol 33, 2015 (suppl; abstr TPS637)
150. Spraggs CF, Parham LR, Warren L, Williams LS, Briley LP, Fraser D, Jiang Z, Aziz Z, Tong Z, Moodley SD, Mehta AO, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow J, Crescenzo R, Armour AA. HLA-DRB1*07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO. J Clin Oncol 33, 2015 (suppl; abstr 617)
151. Gralow J, Barlow WE, Paterson AHG, Lew D, Stopeck A, Hayes DF, Hershman DL, Schubert M, Clemons MJ, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino AJ, Margolis JH, Dakhil SR, Chew HK, Livingston RB, Hortobagyi GN. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. J Clin Oncol 33, 2015 (suppl; abstr 503)
152. Greenlee H, Lew L, Hershman DL, Pierce JP, Hansen LK, Newman VA, Korner J, Sayegh A, Fehrenbacher L, Lo SS, Klemp JR, Rinn K, Robertson JM, Unger JM, Gralow J, Albain KS, Krouse RS, Fabian CJ. Phase II feasibility study of a physical activity and dietary change weight loss intervention in a subset analysis of breast cancer survivors (SWOG S1008). J Clin Oncol 33, 2015 (suppl; abstr 9572)
153. Cherbavaz DB, Hayes DF, Qu K, Crager MR, Barlow WR, Goddard AD, Beasley EM, Jeong J, Collin F, Liu M-L, Rae JM, Ravdin PM, Tripathy D, Gralow JR, Livingston RB, Osborne CK, Ingle JN, Pritchard KI, Davidson NE, Carey LA, Sing AP, Baehner FL, Hortobagyi GN, Shak S, Albain KS. Successful whole transcriptome analysis of 25-year-old breast tumor samples from the phase III

trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies. San Antonio Breast Cancer Symposium 2015, abstract P5-07-01

154. Specht JM, Partridge S, Chai X, Novakova A, Peterson L, Shields A, Guenthoer J, Linden HM, Gralow JR, Gadi V, Korde L, Hills D, Hsu L, Hockenbery DM, Kinahan P, Mankoff DA, Porter PL. Multimodality molecular imaging with dynamic 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and MRI to evaluate response and resistance to neoadjuvant chemotherapy (NAC). San Antonio Breast Cancer Symposium 2015, abstract P5-01-02
155. Kadlubar SA, Barlow WE, Mehta RS, Daniels JR, Albain KS, Vandengerg TA, Dakhil SR, Tirumali NR, Lew DL, Gralow JR, Livingston RB, Hortobagyi GN, Hayes DF, Rae JM. Association between gene variants in SULT1A1 and UGT1A4 and disease outcomes in patients enrolled in SWOG S0226 and treated with anastrozole alone or in combination with fulvestrant for metastatic breast cancer. San Antonio Breast Cancer Symposium 2015, abstract P3-07-64
156. Albain KS, Cragger MR, Barlow WE, Baehner FL, Bergamaschi A, Rae JM, Ravdin PM, Tripathy D, Gralow JR, Livingston RB, Osborne CK, Ingle JN, Pritchard KI, Davidson NE, Carey LA, Cherbavaz DB, Sing AP, Shak S, Hortobagyi GN, Hayes DF. Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814. San Antonio Breast Cancer Symposium 2015, abstract S3-02
157. Chavez-MacGregor M, Barlow WE, Puzstai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Gralow J, Lew DL, Hortobagyi GN. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140). San Antonio Breast Cancer Symposium 2015, abstract OT1-03-11
158. Cardoso F, Beishon M, Cardoso MJ, Corneliussen-James D, Gralow J, Mertz S, Papadopoulos E, Paonessa D, Peccatori F, Sabelko K, Sakurai N, Spence D, Mayer M. Global Status of Advanced/Metastatic Breast Cancer (ABC/mBC): A Decade Report 2005-2015. European Breast Cancer Conference 10, 2015 abstract 7LBA
159. Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Zujewski JA, Azim Jr HA, Judith J, Andersson M, Cufer T, Simon S, Salman P, Toi M, Harris L, Gralow J, Macoon K, Moreno-Aspitia A, Piccart M, De Azambuja E. The impact of diabetes and metformin usage on the outcome of HER2 positive primary breast cancer patients. Analysis from the ALTTO phase III randomized trial. European Breast Cancer Conference 10, 2015 abstract 126
160. Specht JM, Peterson L, Novakov A, O'Sullivan JN, O'Sullivan F, Shields A, Montgomery S, Linden HM, Gralow J, Ellis GK, Gadi VK, Barlow WE, Doot RK, Schubert EK, Dunnwald LK, MacDonald L, Kinahan P, Mankoff DA. Serial FDG-PET to predict response, time to skeletal related events, and survival in patients with bone-dominant metastatic breast cancer. J Clin Oncol 34, 2016 (suppl; abstr 11569)
161. Lemieux J, Goss PE, Parulekar WR, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Strasser-Weippl K, Brundage MD, Whelan K, Tu D, Whelan TJ. Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5

years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. *J Clin Oncol* 34, 2016 (suppl; abstr LBA506)

162. Roberts TK, Peterson L, Kurland B, Novakova A, Shields A, Doot RK, Schubert EK, Gadi VK, Specht JM, Gralow J, Eary JF, Muzi M, Link J, Krohn KA, Mankoff DA, Linden HM. Use of serial 18F-Fluorothymidine (FLT) PET and Ki-67 to predict response to aromatase inhibitors (AI) in women with ER+ breast cancer. *J Clin Oncol* 34, 2016 (suppl; abstr e12039)
163. Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon KA, Whelan TJ, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer EP, Hudis CA, Stopeck A, Beck AJT, Kaur JS, Whelan K, Tu D, Parulekar WR. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. *J Clin Oncol* 34, 2016 (suppl; abstr LBA1)
164. Dvaladze A, Duggan C, Gralow JR, Anderson BO. Breast Cancer Initiative 2.5 (BCI2.5): a global campaign to reduce disparities in breast cancer outcomes. *Journal of Global Oncology* 2:3 (suppl), 21s-22s, 2016
165. Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, Yoshizawa CN, Whelan TJ, Davidson NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, Gralow JR, Hortobagyi GN, Hayes DF, Albain KS. The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814. *Int J Radiat Oncol Biol Phys* 96(2S): S146, 2016.
166. Specht JM, Gadi VK, Gralow JR, Korde LA, Linden HM, Salazar LG, Rodler ET, Cundy A, Buening BJ, Baker KK, Redman MW, Kurland BF, Garrison MA, Smith JC, vanHaelst C, Anderson JE. Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib. *San Antonio Breast Cancer Symposium* 2016, abstract P4-22-11
167. Cho E, Wu Q, Rubinstein L, Linden H, Gralow J, Specht J, Gadi V, Ellis G. Weekly doxorubicin and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer. *San Antonio Breast Cancer Symposium* 2016, abstract P5-14-10
168. Albain KS, Cragger MR, Barlow WE, Baehner FL, Bergamaschi A, Rae JM, Ravdin PM, Tripathy D, Gralow JR, Livingston RB, Osborne CK, Ingle JN, Pritchard KI, Davidson NE, Carey LA, Cherbavaz DB, Sing AP, Shak S, Hortobagyi GN, Hayes DF. Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer –new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814. *San Antonio Breast Cancer Symposium* 2016, abstract PD7-07
169. Pelekanou V, Barlow WE, von Wahlde M-K, Brad WassermanB, Lo Y-C, Hayes DF, Hortobagyi GN, Gralow J, Tripathy T, Livingston RB, Porter P, Nahleh ZA, Rimm DL, Pusztai L. Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial. *J Clin Oncol* 35, 2017 (suppl; abstr 519)
170. Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn K, Albain KS, Chew HK, Von Burton G, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow J, Hortobagyi GN. SWOG S0221 updated: Randomized

comparison of chemotherapy schedules in breast cancer adjuvant therapy. *J Clin Oncol* 35, 2017 (suppl; abstr 521)

171. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NL, Lew DL, Hayes DF, Gralow JR, Linden HM, Livingston RB, Hortobagyi GN. A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226. San Antonio Breast Cancer Symposium 2017, abstract PD5-07
172. Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Moseley A, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final analysis of SWOG S0230/Prevention of early menopause study (POEMS). San Antonio Breast Cancer Symposium 2017, abstract P1-15-01.
173. Gralow J, Olopade F, Ginsburg O. Improvement in the Understanding of Global Health Disparities: Ongoing and Recommended Solutions: Opportunities for international partnering in cancer diagnosis and treatment. AACR SY03, 2018.
174. Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, Dakhil SR, Minasian LM, Wade JL, Fisch MJ, Henry NL, Hershman DL. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). *J Clin Oncol* 36, 2018 (suppl; abstr 10000)
175. Antone N, Kizub D, Gralow J, Zujewski JA, and Dvaladze A. Identifying Facilitators and Barriers to Patient Advocacy for Women's Cancers: Findings from Eastern Europe/Central Asia WE CAN Summits. *J Global Oncol* 2018 4 (Supplement 3, 3s-3s)
176. Kizub D, Miao J, Stopeck A, Thompson P, Paterson AH, Clemons M, Dees EC, Ingle JN, Falkson CI, Barlow W, Hortobagyi GN, Gralow JR. Statin use, site of recurrence, and survival among postmenopausal women taking bisphosphonates as adjuvant therapy for breast cancer (SWOG S0307). San Antonio Breast Cancer Symposium 2018, abstract P1-17-03
177. Goodwin PJ, Segal R, Vallis M, Ligibel JA, Pond GR, Robidoux A, Findlay BP, Gralow JR, Mukherjee SD, Levine MN, Pritchard KI. Lifestyle intervention study (LISA) in early breast cancer (BC): An RCT of the effects of a telephone-based weight loss intervention (with educational materials) vs educational materials alone on disease-free survival (DFS). San Antonio Breast Cancer Symposium 2018, abstract PD6-04
178. Langer S, Todd M, Romano J, Syrjala K, Bricker J, Bolger N, Burns J, Ghosh N, Puleo B, Keefe F, Strauman T, Gralow J, Shankaran V, Westbrook K, Zafar Y, & Porter L. Using smartphone-based technology to examine intra- and inter-personal associations of communicative behavior with mood and relationship satisfaction among patients with cancer and their spousal caregivers. *International Journal of Behavioral Medicine* 2018, 25(Suppl. 1), S119-120.
179. Langer S, Todd M, Burns J, Romano J, Bolger N, Bricker J, Syrjala K, Keefe F, Strauman T, Ghosh N, Puleo B., Gralow J, Shankaran V, Westbrook K, Zafar Y, & Porter L. A smartphone-based approach to gathering twice-daily reports of communication and mood among couples coping with cancer. *Annals of Behavioral Medicine* 2018, 52, S-229.

180. Gralow J. Late recurrence in ER-positive breast cancer. San Antonio Breast Cancer Symposium 2018, abstract ES-53
181. Kizub D, Dvaladze A, Zujewski J, Gralow JR. Patient Advocacy Approaches to Advancing Cancer Access to Care for Women's Cancers in East and Southern Africa. Summit on National and Global Cancer Health Disparities, Seattle, WA, April 2019 (poster)
182. Hershman DL, Unger JM, Grace H, Anna Moseley A, Arnold KB, Dakhil SR, Esparaz B, Kuan MC, Graham M, Lackowski DM, Edenfiel WJ, Dayao ZR, Gralow J, Ramsey S, Neugut AI. Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105. J Clin Oncol 37, 2019 (suppl; abstract 6516)
183. Van Poznak CH, Unger JM, Darke AK, Moinpour C, Bagramian RA, Schubert MM, Hansen LK, Floyd JD, Dakhil SR, Lew DL, Wade JL, Fisch MJ, Henry NL, Hershman DL, Gralow J. Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211. J Clin Oncol 37, 2019 (suppl; abstr 11502)
184. Kizub D, Miao J, Schubert MM, Paterson AHG, Clemons MJ, Dees EC, Ingle JN, Falkson CI, Barlow WE, Hortobagyi GN, Gralow J. Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG 0307 trial. J Clin Oncol 37, 2019 (suppl; abstr 552)
185. Yung RL, Miao J, Paterson AHG, Clemons M, Elizabeth C Dees EC, Ingle JN, Falkson CI, Barlow W, Hortobagyi GN, Gralow JR. Fractures in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG S0307 trial. San Antonio Breast Cancer Symposium 2019, abstract P2-18-02.
186. Hershman DL, Unger JM, Moseley A, Hillyer GC, Arnold KB, Gralow JR, Henry NL, Ramsey SD, Neugut AI. Baseline patient reported outcomes predict aromatase inhibitor adherence failure among women in enrolled in a randomized trial of text-messaging. San Antonio Breast Cancer Symposium 2019, abstract PD10-08.
187. Harbeck N, Im S-A, Barrios CH, Bonnefoi HR, Gralow J, Toi M, Ellis P, Gianni L, Swain SM, Im Y-H, De Laurentiis M, Nowecki Z, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Krop IE. Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). J Clin Oncol 38: 2020 (suppl; abstr 500)
188. Hershman DL, Moseley A, Arnold KB, Hillyer G, Gralow J, Henry NL, Neugut AI, Ramsey SD, Unger JM. Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105). J Clin Oncol 38: 2020 (suppl; abstr 12019)
189. Sharma P, Rodler E, Barlow WE, Gralow J, Huggins-Puhalla SL, Anders CK, Goldstein LJ, Brown-Glaberman UA, Huynh T-T, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN. Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline *BRCA*-associated breast cancer (SWOG S1416). J Clin Oncol 38: 2020 (suppl; abstr 1001)

190. Menon M, Orem J, Adams S, Bakenga A, Basemera D, Kasozi D, Konnick EQ, Mubiru K, Mulumba Y, Muwonge C, Okoche L, Pierce R, Gralow J, Niyonzima N. ER, PR, and HER2 expression in Ugandan breast cancer patients: An evaluation of in-country RT-PCR compared to IHC. *J Clin Oncol* 38: 2020 (suppl; abstr e19009)
191. Langer S, Todd M, Bricker J, Romano J, Syrjala K, Bolger N, Strauman T, Baucom D, Keefe F, Burns J, Ghosh N, Shankaran V, Gralow J, Zafar Y, Westbrook K, Martins R, Porter L. The social cognitive processing model of emotional adjustment to cancer: support from a smartphone-enabled ecological momentary assessment study. *International Journal of Behavioral Medicine* 2020
192. Langer S, Todd M, Romano J, Bolger N, Bricker J, Syrjala K, Burns J, Keefe F, Strauman T, Gralow J, Westbrook K, Shankaran V, Zafar SY, Martins R, Ghosh N, Porter L. The relationship intimacy model of couple adaptation to cancer: support from a prospective, longitudinal, smartphone-enabled ecological momentary assessment study. *Annals of Behavioral Medicine* 2020, 54(Suppl. 1), S142
193. Manohar P, Bastys K, Tratt M, Gralow J, Eaton KD. Practice Patterns in Bone Modifying Agent Utilization: An Analysis in Patients with Metastatic Cancer and Bone Involvement at an NCI Designated Cancer Center. *ASCO Quality Care Symposium* 2020.
194. Paoletti C, Barlow WE, Bergqvist M, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Priyanka Sharma P, Andrew K. Godwin AK, Alastair M. Thompson AM, Daniel F. Hayes DF, Rae J. Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial. *San Antonio Breast Cancer Symposium* 2020, abstract PS2-04.
195. Burton KA, Konnick EQ, Blau S, Dorschner MO, Gralow J, Parulkar R, Mahen E, Spilman P, Parker S, Senecal FM, Pritchard C, Szeto C, Zhu J, Gadi VK, Benz SC, Rabizadeh S, Soon-Shiong P, Blau CA. Multidimensional molecular profiling of repeated metastatic TNBC biopsies in the intensive trial of omics “ITOMIC” safely guides treatment decisions. *San Antonio Breast Cancer Symposium* 2020, abstract PS11-13.
196. Kalinsky K, Barlow WE, Meric-Bernstam F, Gralow JR, Albain KS, Hayes D, Lin N, Perez EA, Goldstein LJ, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martín M, Gil MG, Arce-Salinas C, Brain E, Park IH, Pierga J-Y, Lluch AH, Vasquez MR, Borrego MR, Jung KH, Ferrero J-M, Schott A, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Hortobagyi GN, Pusztai L. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder) *San Antonio Breast Cancer Symposium* 2020, abstract GS3-00.
197. Gralow J, Orem J, Abdul Jabbar A, Dalichow F, Moore C. Taking Care of Patients with Cancer in Resource-Limited Settings. *ASCO annual meeting education session*, 2021.
198. Gralow J and Cance W. Satellite session: Clinical Trials in Low- and Middle-Resource Settings - A Focus on Africa. *Accelerating Anti-Cancer Agent Development and Validation (AAADV) virtual meeting*, 2021.

199. Kalinsky KM, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LA, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga J-V, Bermejo B, Ramos-Vasquez M, Jung KH, Ferrero J-M, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Puztai L, Hortobagyi G. Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER). San Antonio Breast Cancer Symposium 2021, abstract GS2-07.
200. Gralow JR. Cancer Care During the War in Ukraine. ASCO Annual Meeting 2022 education session.
201. Bruinooge SS, Kurbegov D, Kaltenbaugh M, Hanley Williams J, Gralow JR, Garrett-Mayer E. Breakthrough COVID-19 cases and hospitalization risk: ASCO COVID-19 registry. J Clin Oncol 40, 2022, abstract e18807.
202. Kizub D, Gralow JR. Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials – Is Africa the Answer? UICC World Cancer Congress 2022.
203. Gralow JR. Integration of Palliative Care into Standard Oncology Care: Is it working? UICC World Cancer Congress 2022.
204. Gralow JR. Availability and Accessibility of Essential Cancer Drugs. UICC World Cancer Congress 2022.
205. Gralow J and Fleming T. The Opportunity for Global Cancer Drug Development. Accelerating Anti-Cancer Agent Development and Validation (AAADV) meeting, 2022.
206. Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SK, Dhesy-Thind S, Rastogi P, Alba E, Delalogue S, Schott A, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Puztai L, Hortobagyi GN, Kalinsky K. GS1-01 Race and clinical outcomes in the RxPONDER Trial (SWOG S1007). San Antonio Breast Cancer Symposium 2022, abstract GS1-01.
207. Kang I, Forschmiedt JK, Loch MM, Barlow WE, Lew DL, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Miao J, Tripathy D, Puztai L, Hortobagyi GN, Kalinsky K, Henry NL. Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status. San Antonio Breast Cancer Symposium 2022, abstract GS1-04.
208. Chavez M, Miao J, Puztai L, Goetz MP, Rastogi P, Ganz PA, Mamounas E, Paik S, Bandos H, Razaq W, O'Dea A, Kaklamani V, Silber ALM, Flaum LE, Andreopolu E, Baar J, Wendt AG, Carney JF, Sharma P, Gralow JR, Lew DL, Barlow WE, Hortobagyi GN. Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207. San Antonio Breast Cancer Symposium 2022, abstract GS1-07.
209. Cobain E, Barlow W, Paoletti C, Bergqvist M, Williams A, Ritzen H, Mehta R, Gralow J, Hortobagyi G, Albain A, Puztai L, Sharma P, Godwin A, Thompson A, Hayes H, Rae J. Comparing

the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226. J Clin Oncol: 2023 (suppl; abstr 1076)